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                                                      ABSTRACT 
 BACKGROUND:  
Tumors of salivary gland have diverse histological forms and unpredictable clinical behavior. 
The diverse site of origin and complexity of classification further compound the difficulties in 
diagnosis. The main application of immunohistochemistry in salivary gland tumors is to 
demonstrate the existence of myoepithelial/basal cells or luminal cells. 
OBJECTIVES: 
 1. To determine the incidence, age, sex, site distribution of lesions in various salivary glands and 
to study the histomorphological appearance of these lesions. 2. To study the expression of 
various  Immunohistochemical markers in salivary gland tumors. 
METHODS:  
Surgically resected specimens received at Department of pathology, Thanjavur medical college 
were subjected to histopathological examination. Specimen were fixed in 10% formalin, 
processed and embedded in paraffin blocks. Serially cut to get sections of 3-5microns thickness, 
stained with Hemotoxylin and Eosin, Histochemistry and Immunohistochemistry were done 
wherever necessary. 
RESULTS: 
The total number of specimens was 92, of which 41were neoplastic (benign44.56% and 
malignant 25%) 28 were nonneoplastic. Pleomorphic adenoma was the commonest benign tumor 
accounting for73.17% of benign tumors. Mucoepidermoid carcinoma was the most common 
malignant tumor accounting for 52.18% of malignant tumors. Parotid is the common salivary 
gland involved followed by minor salivary and submandibular gland.salivary gland tumors 
shows  slight female preponderance with male female ratio of 1:1.7. Expression of p63 in 
pleomorphic adenoma has confirmed the role of myoepithelial cells in the histiogenesis of this 
tumor.  Lack or minimal expression of p63 in Mucoepidermoid indicates minimal myoepithelial 
cell differentiation in these tumors. 
CONCLUSION: 
Histopathology is still  the goldern standard for diagnosis of salivary gland tumor. IHC do not  
direct ly ind icate a definite diagnosis.  It  can enhance the accuracy  and be a helpful tool  
when the diagnosis cannot be assessed by histological examination such as cell of origin, cell 
proliferation and tumor protein expression.  
Keywords: Pleomophic adenoma, Mucoepidermoid carcinoma, Immunohistochemistry. 
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INTRODUCTION 
 
Salivary glands are exocrine organ responsible for production of saliva  and  are 
the site of non-neoplastic and neoplastic lesions.1 The gland give rise to different types 
of pathological process that contributes to variety of  inflammatory to neoplastic 
lesions.2 Their remarkable morphologic variation make these tumors difficult to 
diagnose3. Due to the lack of universally accepted classification marked variation arise 
in the histological features of this tumor.                                        
The overall incidence of salivary gland tumours is approximately 0.4 to 13.5 
cases per 100000 populations.13 It constitute 3-6% of all head and neck tumors. 
In tumors of salivary glands parotid gland is affected in 64-80% of cases, 
Submandibular gland 7-11%,  Sublingual gland 1% and 9-23% in minor  glands12. 
Palate is the most frequent site3among minor glands . 
Benign tumors are more common(54-79%) when compared to malignant  tumor(21-
46%).12 As  the size of gland decreases the incidence of malignancy increases Least 
being the parotid to maximum in sublingual and minor salivary  gland. 
 Pleomorphic adenoma is the most common benign and mucoepidermoid  being the 
most common malignant tumor. 
Even though salivary gland tumor accounts for less than 5% of all neoplasm, it is 
important because almost all lesions whether benign or malignant will  present as 
swelling of parotid gland.  
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The prognosis is less favorable  in parotid gland, most favourable  in palate, 
and least favorable in submandibular gland with respect to diagnosis, treatment and 
prognosis4.                 
Immunohistochemistry  enhances the accuracy of diagnosis of cases  that 
cannot be assessed by histological examination.Inspite of this  Hematoxylin - Eosin 
staining is the golden  method of diagnosis. Immunohistochemistry   detects  the  nature 
of cell differentiation, cell proliferation and tumor protein expression5. 
Main application of immunohistochemistry in  salivary gland tumor is to 
demonstrate the existence of luminal or myoepithelial/basal component when diagnosis 
is uncertain. Using these particular luminal myoepithelial markers salivary gland tumor 
divided into two groups 
1.Tumors with dual cellular population . 
2.Tumor with single line of diffentiation.19 
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AIM OF THE STUDY 
 
1. To study incidence of salivary gland lesions. 
2. To study the age,  sex,and  site distribution of various  salivary gland  lesions. 
3.  To study the histomorphological appearance of salivary gland lesions. 
4. To evaluate myoepithelial marker p63 in  Pleomorphic Adenoma and 
Mucoepidermoid   carcinoma of  salivary glands  for  differential diagnosis  of these 
tumors   and   specification of  their histiogenesis. 
5.  To study  the  expression  of    various   Immunohistochemical  markers    in  
salivary    gland  tumors. 
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MATERIALS AND METHODS 
Patients presenting with signs and symptoms of salivary gland enlargement in Thanjavur medical 
college hospital, Thanjavur  during the period from September 2011- August2014 were included 
in this study, irrespective of the age group and sex. 
A proforma [Annexure II] was made and all the patients attending the hospital with complaints 
related to salivary glands were made to fill the proforma. 
All the surgical specimens received in the department of pathology were fixed in 10% neutral 
buffered formalin. 
   Grossing of the specimens were done with atmost care, noting the size of the lesion, whether 
they have circumscribed or infiltrative borders and presence of cystic changes were noted with 
special attention to the number of cysts, single or multiple, appearance of the surface, color of 
the walls, presence of papillary projections into the lumen of the cyst wall. All the suspicious 
were grossly sectioned and subjected to histopathological examination. 
Sections were processed as small sections of 2-3mm in thickness in the automatic tissue 
processor and processed in a routine way. 
Sections of 5µ thickness were cut and stained with Hematoxylin and Eosin and in doubtful cases 
slides were submitted for special histochemical stains such as PAS, Alcian blue, Masson 
trichrome were done[Annexure IV]. Histological classifications of these tumors were done as per 
WHO classification[2005] [Annexure III]. 
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Immunohistochemistry of CK, p63, CD117, Her2/neu, Ki67 was done on 
deparaffinized 5µ sections after antigen retrieval by heat using microwave oven 
[Annexure V]. 
The intensity of Immunostaining reaction has been described from literature 
data122 as follows.  
 When the immunostaining  reaction is all  over or intensely 
positive,obvious even in  small magnification[+++] 
 when the immunostaining reaction is focal or with moderate 
intensity,evident on average magnification.[++] 
 When the immunostaining reaction is weak or very focal,visible only at 
strong magnification[+] 
 When the immunostaining reaction is very reduced,to limit[+/-]. 
 when the immunostaining is negative.[-] 
 
Ki-67:    The most stained areas in each section were chosen, and the minimum of 
thousand tumor cells were counted under light microscope fields [X400]. The 
percentage of positive tumor cell nuclei was recorded as labeling index[LI]. 
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REVIEW OF LITERATURE 
Salivary glands are tubulo acinar exocrine organs responsible for production 
and excretion of saliva 
Anatomy.9,10 
Salivary gland comprises three paired major glands. Largest being parotid, 
followed by submandibular and sublingual gland. 
            There are also several hundred minor glands which are distributed throughout 
oral and oropharyngeal submucosa in the upper respiratory and sinonasal tract. 
 Secretory acinus, related ducts and myoepithelial cells are the functional  unit of 
salivary gland. Acinus may be  mucous, serous  or mixed. 
Parotid is the largest of all salivary gland and it  weighs about 14-30gms.  
It is surrounded by thin capsule. Facial nerve divide it into two portions. 
Superficial lobe is flattened and quadrilateral in shape. Majority of  salivary 
gland tumors arise here. 
 Deep lobe is irregular, wedge shaped and is in anatomical relationship with 
parapharyngeal space. Excretory duct of parotid is Stenson’s duct.The duct opens into 
parotid papillae opposite 2nd molar tooth. 
 
SUBMANDIBULAR: 
           It is encapsulated and lies inside the submandibular triangle and weighs 7-8gms. 
It is organized into lobules and  connected to  main excretory duct(Wharthin’s 
duct).Wharthin’s duct opens into a narrow orifice  called caruncula sublingualis.  
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SUBLINGUAL GLAND: 
                      It weighs 3gms and lies in sublingual fossa and surrounded by loose 
connective tissue. It opens through a main duct called Bartholin’s duct, which opens 
into submandibular duct and various small ducts(Rivinus ducts) which joins the 
submandibular duct and opens separately into mouth in plica sublingualis. 
 
MINOR SALIVARY GLANDS: 
More glands are present  at the junction of soft  and hard palate, lip, buccal 
mucosa, tongue, floor of mouth retromolar pad lateral aspect of tongue. In addition 
minor glands are present in ventral surface of tongue(Glands of Blandin and Nuhn) 
Minor glands opens into the groove surrounding the circumvallate papillae(von 
Ebner’s glands) are purely serous in type.  Minor salivary glands are purely serous in 
type.Glands are  not encapsulated and glands in the tongue are deeply located in the 
underlying muscle.  
 
HISTOLOGY OF SALIVARY GLANDS: 
The  secretory acinus  and the  related ducts and myoepithelial cells forms the  
functional unit of salivary gland. 
They are 3 types of secretory units serous, mucous or mixed 
Serous unit contain amylase, mucinous, unit contain sialomucin and mixed unit 
made up of serous and mucous cells. Parotid is of  serous type. Palatal salivary glands 
are predominantly mucous. 
               Submandibular and sublingual are of mixed type. These mixed unit are 
characterized by crescent shaped caps the demilunes of serous cells at the end of 
mucous secreting tubules. 
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ACINI: 
The epithelial cells are pear shaped in serous acini , surrounded by a distinct 
basement membrane. The nucleus are basally situated and dense cytoplasm packed with 
PAS  positive zymogen granules. 
Mucinous acini are  irregular in shape with clear  cytoplasm filled with vacuoles 
of sialomucin(Alcian blue and mucicarmine +ve) and neutral sialomucin(PAS +ve) 
 
DUCTS: 
The intercalated and striated ducts are intra lobular and are called as secretory 
duct. Excretory ducts are interlobular. 
           Intercalated   ducts are  lined by single layer of cuboidal epithelium and an 
irregular myoepithelial cells. The striated ducts are lined by simple columnar 
epithelium.The principle duct consist of thick external fibrous coat of collagen and 
elastic fibres.  Near the opening of mucous membrane the epithelium is stratified 
squamous.   
 
BASKET CELLS OR MYOEPITHELIAL: 
These are  located between basement membrane and basal plasma membrane of 
acinar cells and  are contractile in nature. There is only one myoepithelial cell for each 
secretory unit. 
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                                                EMBRYOLOGY 
Salivary gland development begins in 5th-6th week of age, when parotid gland 
primordial appears. Submandibular primordia develop at  6th week, sublingual 
primordial at 7th to 8th week and  intra oral minor salivary glands at 3rd month of 
gestation. 
Salivary gland arise as buds of proliferative epithelium from the primitive 
stomodeum(oral cavity).The stomodeum epithelium is partly endoderm and ectoderm. 
Oral ectoderm give rise to parotid gland where as endoderm give rise to submandibular 
and sublingual gland. Initially the epithelial cords and bulbs are without lumen. 
Luminization occurs 1st in the epithelial cord and progress to terminal bulbs. Cellular 
differentiation results in the characteristic features of excretory ducts and acini. 
            Proximal branched cords  become excretory and main ducts. Distal branched 
cords become striated ducts and the luminized terminal bulbs become intercalated ducts 
and acini. 
            The parotid gland is colonized by lymphocytes at 3rd month of gestation. These 
subsequently develop into several intraparotid and periparotid lymphnodes. These 
nodules lack the complete organization of lymph node. 
 
DEVELOPMENTAL DISORDERS: 
During the normal course of human development  aberration of salivary glands 
can occur. 
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HETEROTOPIC SALIVARY GLAND:  
Heterotropia  is a  supernumerary normal structure in an abnormal location. 
            Salivary gland has  been described in variety of aberrant locations hypophysis, 
cerebropontine angle, middle ear,16mastoid, auditory canal, tongue, palatine tonsil, 
thyroglossal duct, mandible, thyroid, parathyroid capsules and sternoclavicular joint. 
These are more common in lymph node near parotid gland. 
Salivary gland elements are seen in association with developmental lesions such 
as branchial cyst.  
Shin C Kim etal17 in 2000 reported a case of choristoma of the anterior chest 
wall.  
ACCESSORY PAROTID GLAND:  
           The term “accessory gland” refers to lobules of parotid that are separated from 
the body of parotid and opens into Stenson’s duct. Length of accessory parotid duct 
0.5-3cms. Clinically lesions of accessory  parotid tissue  are present as masses in cheek. 
 
ONCOCYTOSIS:   
It  was first described by Schaffer and later the term was applied by Hamperl. 
Oncocyte are  cell  with  numerous number of cytoplasmic mitochondria. The 
proliferation of oncocyte without any pathological significance is called oncocytosis or 
oncocytic metaplasia. Majority of cases are found in the parotid gland7.. Histologically 
present as solitary foci of enlarged eosinophilic epithelial cells. 
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ADENOMATOID HYPERPLASIA OF MUCOUS GLANDS: 
Synonym: Hamartomatous proliferation of minor salivary gland. Clinically present as 
mass in palate that is covered with bluish or normal mucosa but shows no ulceration or 
pain. 
 
MICROSCOPIC FEATURES: Mucosa  shows  pseudoepitheliomatous  hyperplasia 
with underlying connective tissue contains enlarged lobules of normal appearing 
mucous acini and ducts. Salivary tissue is described as hyperplastic when present in 
greater than normal amounts and crowded. 
 
POLYCYSTIC(DYSGENETIC) DISEASE OF PAROTID: 
 It is developmental malformation of duct system usually affect both salivary glands. 
Commonly affects female offspring and present as recurrent painless swelling. 
GROSS: Lobular, cut surface shows mottled yellow and ivory nodules with a fine 
spongy consistency. 
MICROSCOPY: Architecture is maintained, lobules are markedly distended  which 
impact a honey combed or lattice like appearance. Small residual island of glandular 
acini are present between the cyst which vary in size and lined by flattened cuboidal or 
columnar epithelium.14 Occasionally apocrine cells are seen in the luminal border. 
 
OBSTRUCTIVE DISORDERS:  
 Can occur in major or minor salivary glands   
 1. Occur as a result of stasis of salivary secretion  in ducts. 
 2. Partial or complete block of excretory ducts. 
 3. Traumatic severance of salivary ducts. 
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         Three common primary obstructive condition are  
 1)Mucocele, 2)Mucous retention cyst, 3)Sialolithiasis. 
 
 MUCOCELE11,12. 
Most common non neoplastic lesion  with prevalence of 1.4/1000. These are 
pools of saliva within a cystic cavity. 
           Edmund et al conducted  study of 594 cases in which majority of mucocele 
occurs in lower lip. Seen in the age group 11-20 years. Peak incidence of mucous 
retention cyst occur in 7th-8th decade of life. Clinically mucocele manifest as painless 
soft and fluctuant, dome shaped mucous nodules which are 0.2-1cm. Large mucoceles 
of floor of the mouth are referred as ranula. If they extend into cervical tissues-plunging 
ranula. 
 
MICROSCOPY: Mucous escape reaction with a pool of mucous in fibrous connective 
tissue, surrounded by inflammatory cells predominantly  macrophages. These mucus 
are highlightened by mucicarmine stain.11   
 
MUCOUS RETENTION CYST OR SIALOCYST: Less common than mucocele, 
develop as a result of cystic dilatation due to obstruction of  major salivary gland. 
Average age at presentation is 50 years. Mucous retention cyst of parotid is known as 
salivary gland cyst and is true cyst lined by epithelium. Lesions are  mostly unilocular. 
 
MICROSCOPY: Epithelial lined fibrous tissue around the mucous pool. The 
epithelium may be cuboidal, columnar or stratified squamous. Lumen of cyst may be 
filled with an eosinophilic material that stains positive for mucin18. 
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SIALOLITHIASIS.10,11,12. 
It denotes various calcified masses that are formed  in ducts of salivary gland24. 
It occurs as a result of mineralization of debris that has accumulated in the lumen of 
duct. According to published data, salivary stones are localized in submandibular 
glands in 80-90% of sialolithiasis cases. They vary in shape ranging from 2mm-2cms25. 
 
SIALADENITIS:(10,11,12.) 
Inflammation of salivary gland  due to mechanical, physical, microbial, and 
immunological factors.  Radiation is an important physical cause of sialadenitis. Serous 
acini of parotid gland are radiosensitive. Acute inflammatory response occur initially 
followed by chronic  sialadenitis and  xerostomia24. 
 
ACUTE SIALADENITIS:(10,11,12) 
 Infection occurs due to decreased salivation and  patient  present with a state of 
dehydration.  Infants in tube feeding  are at risk of neonatal sialadenitis due to 
staphylococcus aureus and pseudomonas aeruginosa12infection. 
 
CHRONIC SIALADENITIS10,11. 
It is a non granulomatous chronic inflammatory disorder of salivary glands due 
to physical, microbial or immunological factors.  
 
KUTTNER TUMOR OR CHRONIC SCLEROSING SIALADENITIS: This was 
described by Kuttner in 1896. It is a benign inflammatory process occurring almost 
exclusively in submandibular gland of middle aged adults. 
MICROSCOPY: Initial phase shows  chronic inflammation, duct ectasia with 
periductal fibrosis followed by acinar atrophy, fibrosis  ductal dilatation and sclerosis in 
late stage139. 
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INFECTIOUS SIALADENITIS 
TUBERCULOSIS10,11  The most common  infection of that affects salivary gland is 
Mycobacterial adenitis involving the periparotid and intra parotid lymph nodes 
followed by other salivary glands. Symptoms manifest only at late stage of disease. 
MICROSCOPY:  Shows necrotising granulomatous inflammation with caseous center 
surrounded by epitheloid cells, langhans  and foreign body giant cells. 
 
VIRAL SIALADENITIS10,11. 
MUMPS: The most common cause of parotid  swelling are viral agents. Peak age of 
incidence is 4-6yrs. 
MICROSCOPY: Shows  ductal dilatation, acinar cell vacuolization and dense 
lympho-plasmacytic infiltrates. 
CYTOMEGALOVIRUS:(CMV) Most people are infected with cytomegalovirus at 
some point in their life. The age of incidence varies world wide. In developing 
countries most infection is  acquired during childhood. CMV  can be sexually 
transmitted and via breast milk, organ transplantation and rarely blood transfusion. 
MICROSCOPY: Hallmark of CMV infection in salivary gland is an enlarged duct 
cells with characteristic intranuclear viral inclusion bodies-owl’s eye  appearance. 
 
 HIV ASSOCIATED LYMPHOEPITHELIAL CYST: 
Nodular or diffuse enlargement of salivary gland  occurring  in patient with HIV 
infection  is called as HIV associated LEC, HIV-salivary gland disease, benign 
lymphoepithelial lesion. 
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GROSS: Multiple cyst of variable diameter upto 5cm can be seen usually in the 
superficial lobes of parotid with preservation of gland  architecture. . 
MICROSCOPY: Shows poorly circumscribed multinodular areas composed of 
multicystic structures surrounded by dense lymphoid infiltrate with florid lymphoid 
follicular hyperplasia and lymphoepithelial lesion. 
The cyst are lined predominantly by non keratinizing, stratified squamous 
epithelium and focally by cuboidal type cells permeated by monocytoid/marginal zone-
B cells and also sparsely by T-cells present within the lymphoid infiltrate.  
 
                                       BENIGN CYSTS OF PAROTID10,11. 
LYMPHOEPITHELIAL CYST(LEC): 
1)  These are uncommon, mostly arising  from Neisse Nicholson rests of parotid 
gland. 
Average age of patient is 45yrs present as a painless mass. Cyst measures 6cm 
in diameter(average 2.5cms). 
  GROSS: Predominantly unilocular  cyst with yellow white caseous material. 
MICROSCOPY: Epithelial cyst wall contain dense lymphoid tissue  with 
prominent germinal centre.Lining is usually stratified squamous but focal areas 
of respiratory or  cuboidal   epithelium can occur. 
 Differential diagnosis:  1)Warthin’s tumor, 2)True branchial cleft cyst. 3)Low 
grade MEC 4)Cystic LESA. 
2) SALIVARY DUCT CYST:10,11 salivary duct cyst or sialocyst arise in parotid 
gland. Occurs in 4th decade.                  
GROSS: Cyst usually present as a unilocular painless swelling, size            
measures upto 3cms in  diameter 
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MICROSCOPY: Luminal surface is covered by cuboidal or squamous 
epithelium with chronic inflammation of the collagenous wall. 
 
BENIGN LYMPOEPITHELIAL LESION10,11 
Godwin in 1952 proposed the name Benign lympoepithelial lesion to describe 
parotid lesion previously called Mikulicz disease. Berner and Bhaskar10 suggested that 
Benign lympoepithelial lesion is neither a neoplasm nor a lesion in which epithelium 
plays an aggressive or dominant role. It is a primary lymphoid lesion that can involve 
the salivary gland. 
Age: 1-86yrs 
Females>Males. (average age 51yrs for female and 45yrs for male) 
83% occur in parotid. 
11% submandibular gland. 
6% in minor salivary gland. 
GROSS: 1-2cms in size, well circumscribed. 
MICROSCOPY: Epithelium lined by multiloculated cystic space encased by 
lymphoid tissue, plasma cells and germinal centers. 
 
SJOGREN’S SYNDROME:10,11. 
First described in 19th  century by Haldane. Mikulicz a few years later it was 
named after ophthalmologist Sjogren whose classic report of this appeared in 1993. 
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            Sjogren’s  is a chronic lymphoproliferative disorder which may present as a 
primary or secondary disease. The histopathology substrate is characterized by 
presence of lymphocytic infiltrate in glandular and extra glandular site. 
MICROSCOPY: Shows the  presence of lymphocytic infiltrate in glandular and extra 
glandular site. 
KIMURA’S DISEASE: Kimura’s is an angiolymphoid proliferative disorder of soft 
tissue with eosinophilia and elevated IgE levels. According to Kung et al Kimura’s 
disease was first described in China during 1937. This title came after Kimura et al who 
reported a similar case  in 1948. It occur predominantly in young and middle aged. 
Mean age 27-40yrs. M>F. Rosai et al22 were first to note that Kimura disease is 
different from angiolymphoid hyperplasia. It occur mainly around the ear with frequent 
involvement of salivary gland. 
GROSS: The lesions are rubbery and irregular or nodular. 
C/S: Grey to light brown and may contain embedded lymph nodes and attached 
salivary glands and muscle. 
MICROSCOPY: Uncapsulated lesion characterized by  fibro collagenous tissue, 
lymphoid tissue and mixed inflammatory cell infiltrate with numerous eosinophils. 
Eosinophilic abscess, polykaryocytes of Warthin- Finkeldey are sometimes  present in 
germinal centres . 
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TUMOUR LIKE LESIONS:10,11,12 
NECROTIZING SIALOMETAPLASIA: 
Benign self limiting reactive inflammatory  condition  salivary gland.First 
reported in minor salivary gland of hard palate by Abram’s et al in 1973.  It clinically 
and histologically simulates  MEC, SCC. 
ETIOLOGY: 
Ischemia caused by impairment of vascular supply to salivary gland tissue has 
been implicated as the most likely etiology for this disease. By both clinical and 
experimental evidence, lesions are associated with trauma, local anaesthetic injection, 
allergy. 
EPIDEMIOLOGY: 
Accounts  for  0.3% of all biopsied lesion of oral cavity. Most cases occur in 
palate(77.2% ). Others include minor salivary glands of lower lip, retromolar pad area, 
tongue , buccal mucosa and major salivary gland(8.7%).   
Age: Average 45.9yrs:  Sex: M:F 2:1. 
CLINICAL FEATURES:  Deep crater like ulcer of palate that resembles a malignant 
process. Lesions  ranges from 0.5cm-5cms in size.  
MICROSCOPY: Lobular infarction or necrosis of acini, squamous metaplasia of 
residual acini and ducts are predominant .  Squamous cell nucleus appears bland. 
Lymphocytes and neutrophils infiltrates the surrounding tissue. Lobular architecture 
will be maintained despite extensive metaplastic and inflammatory changes.  
DD: Squamous cell carcinoma, MEC, Coagulative necrosis of acini. 
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SCLEROSING POLYCYSTIC ADENOSIS: First reported by Smith and 
colleagues in 1996 from Armed Force Institute of pathology. Characterized by 
sclerosed, collagenous tissue surrounding ill defined  acinar  and ductal  lobules with 
cystically dilated duct structures.  Age: 9-75yrs with Male:Female ratio of 14:22. 
Site: Most often occur in parotid gland.  
 
GROSS: Lesions are well circumscribed, multifocal rubbery nodules with size ranging   
from 1cm-7cms.  
Cut section: Pale and glistening. Some tiny visible cysts range from 1-2mm in 
diameter. 
 
MICROSCOPY: Sclerosed, collagenous tissue surrounding  ill defined  acinar  and 
ductal  lobules with cystically dilated duct structures. Staining with myoepithelial 
markers shows the presence of myoepithelial  cells that surrounds the lobules and ducts.  
DD:  Adenocarcinoma NOS: Acinic cell carcinoma, Cystadenoma. 
Presence of peripheral myoepithelial layer, lack of evidence of infiltration and lobular 
nature should prevent confusion from its mimickers.  
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ETIOLOGY OF SALIVARY GLAND NEOPLASMS 10,11,15. 
 
In  general little known about the cause of salivary gland neoplasms. 
Many factors have been implicated in the causation of salivary gland tumor. 
 
1. VIRUSES: The Epstein-Barr viruses and possibly auto-immunity leads  to 
salivary gland carcinoma referred to as malignant lymphoepithelial lesions.  
Studies on  human pleomorphic adenoma shows the presence of SV40 (Simian 
virus 40) DNA sequences and SV40 large T antigen. 
 
2. RADIATION: An association between  high dose radiation and salivary gland 
cancer is seen in studies of atomic bomb survivors. Iodine131 used to treat 
thyroid disease   also concentrated in salivary glands and increases the risk of 
salivary tumors.26.The  risk of  malignant salivary  tumors is increased  in 
patients of childhood cancer in head and neck region, treated by a combination 
of chemotherapy and radiotherapy.27 Recent study of a population shows a 
higher frequency of benign parotid tumors, in a population of higher than 
average mobile telephone users28. 
 
3. OCCUPATION: Certain occupation has been reported  to place people at an 
increased risk. These include asbestos mining, manufacturing of rubber 
products and industries such as shoe manufacturing, plumbing(exposure to 
metals) and working in automobile industries.  
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In Quebec there was an increased risk of salivary cancer among people living 
close to asbestos mines.29 
4. LIFESTYLE AND NUTRITION: John A et al reported close association 
between cigarette   smoking and Warthin’s tumor.10 The incidence is eight times 
that of non smokers. There is high risk of bilateral tumors in heavy cigarette 
smokers8. Exposure to kerosene  and silica dust as a cooking fuel appeared to 
increase the risk in Chinese population.30. 
5. HORMONES: High levels of progesterone receptors have been reported in 
recurrent PA.31. Progesterone receptors are found in acinic cell carcinoma and 
MEC, but not in salivary duct Carcinoma.  90% of salivary duct carcinoma 
shows  Androgen receptors10. 
 
HISTIOGENESIS AND MORPHOLOGY OF SALIVARY GLAND NEOPLASM  
Salivary gland have the greatest diversity of morphologic features among their 
cells and tissue. Although salivary, sweat, apocrine, and mammary glands all have 
similar phylogeny and cellular phenotypes, many lesions are unique to salivary glands. 
HISTIOGENIC ASPECTS:  
It is stated that specific reserve cells or basal cells  of the  intercalated and 
excretory ducts  are   both  responsible for  neoplastic transformation.  
The intercalated duct cells is suggested to be cell of origin for Canalicular 
adenoma, Cellular adenoma, Oncocytoma, Warthin tumor, Papillary adenoma, 
adenocarcinoma, acinic cell carcinoma. 
Excretory duct reserve cell is suggested to give rise to intraductal papilloma, 
PA, epidermoid carcinoma of salivary gland origin and Mucoepidermoid carcinoma.. 
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The theories of tumor origin are based on relationship to salivary gland 
embryogenesis and potentialities of ductal epithelium during reactive process.32 
Regardless of  cell of origin for salivary gland tumors it is essential to appreciate the 
types of cell differentiation,  tumor cell organization,material synthesized by the cells 
and their placement within the tumor. 
 
PLEOMORPHIC ADENOMA10,11,13 
PA (mixed tumor, benign mixed tumor): Benign salivary gland neoplasm 
composed of ductal epithelial and myoepithelial cell proliferation within a 
mesenchymal stroma.According to Frazell and Foote,35 the term mixed tumor dates 
from Minssen’s in 1874 which is cited by Ahlbom.36. 
INCIDENCE: 60% occur in parotid, 40-70% occur in submandibular and minor gland. 
The most common minor salivary gland site are palate, lip, and buccal mucosa. Other 
sites are cervical lymph node ,breast, lung ,mandible , pituitary fossa, lacrimal gland, 
sac, ear. Histologically  it is similar to  tumor of skin-chondroid syringoma. 
Gender/ Race: Female > Male. (1.9:1) 
AGE: 4th – 5th decade 
CLINICAL FEATURES: Asymptomatic, slow growing mass. May become very 
large if neglected 
GROSS: well circumscribed,  variable encapsulated mass usually arise from superficial 
lobe especially lower pole. 10% arise in deep lobe. Cut surface is  white tan, shiny or 
translucent. Mucoid   tumors shows   absence of  capsule in some cases.   
HUMARA (human androgen receptor gene) molecular assay  shows that the  stromal 
and epithelial  cells of pleomorphic adenoma have a common origin.11 
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MICROSCOPY: Shows admixture of mesenchymal and epithelial structures. 
Epithelial element is composed of luminal ductal structures surrounded by 
myoepithelial cells. Stromal or mesenchymal elements are composed of  myxoid, 
chondroid and  hyaline areas.Rarely bone may form directly by stromal osseous 
metaplasia .  PA  in minor glands shows fat cells in the stroma , when the lipomatous 
component is 90% or more it is called-lipomatous pleomorphic adenomas. 
 
CELLULARITY OF PA: when densely  packed solid sheets of epithelial or 
myoepithelial cells occurs it is called- cellular pleomorphic adenomas. 
 
IMMUNOHISTOCHEMISTRY13:Luminal cells of tubuloglandular element of PA 
are positive for CK 3,6,7,10,11,13,16.  Pan-CK, CK 13,14,16 are irregularly positive 
for modified myoepithelial marker.   There are also positive for  vimentin, S-100 and 
GFAP.    Currently  the more reliable marker for  myoepithelial cells  are  p63/Calponin 
which shows intense positivity. C-kit(CD-117) stains the luminal cells of PA.  
 
MOLECULAR GENETICS: Cytogenetics shows recurrent chromosomal aberrations 
in approximately 70% of PA.  
The targeted genes on ch8q and 12q are PLAG1 and HMGA2(formerly known 
as HMGIC) which encodes for transcription factors. Translocations resulting in 
overexpression of their genes has been postulated to play an important role in 
pathogenesisof pleomorphic adenoma. This can be  detected by RT-PCR  or 
fluorescence in situ hybridisation. 
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DD: 
1. Monomorphic adenoma, 
2. Adenoid cystic carcinoma 
3. Epithelial myoepithelial carcinoma 
4. Polymorphic low-grade Adenocarcinoma 
5. Mucoepidermoid carcinoma 
6. Various mesenchymal tumor  such as  nerve sheath tumor, smooth muscle 
tumor. 
MYOEPITHELIOMA:10,11,13 It  accounts for 1-2% of all salivary gland tumors. 
Parotid is the most favorite site. It presents clinically as painless mass. 
MICROSCOPY: Shows sheets and cords of cells which may be may be   spindle, 
plasmacytoid, epitheloid, or clear cell in a collagenous or myxoid stroma.The spindle 
cell type shows fascicular pattern of growth.  
   Three morphologic type are 
1. Spindle, 
2. Hyaline(plasmacytoid)  and 
3. Mixed cell types.  
The mixed cell type contain spindle and plasmacytoid cells in roughly equal 
part.  Positive staining for calponin, actin and p63 indicate that the cells shows 
myoepithelial differentiation. Epithelial cells are large polygonal cells with 
eosinophilic cytoplasm and centrally located bland nuclei. They commonly 
show a lenticular, trabecular or solid growth pattern.  
IHC:13,19 clear cells are rich in glycogen. Pan-CK as well as myoepithelial 
markers(calponin, S-100, GFAP, Actin, CK-14, p63) are generally positive and  usually 
negative for CK-7,EMA, and CEA. 
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BASAL CELL ADENOMA(BCA)10,11,13.  It was first described byKleinsassar and 
Klein in 1967.37   Various patterns described are 
1.Tubular 2.Trabecular, 3 Membranous.4.solid. 
       It accounts for 1%-7.5% of all salivary gland tumors, mainly in minor salivary   
      glands. Peak incidence: 7th decade of life. 
Parotid is the dominant site for occurrence of BCA. 75% occur in parotid followed 
by salivary gland in 5%. Upper lip being most common site in minor glands. It 
presents mostly as a painless mass of long standing duration. 
GROSS:  Round to oval, firm, smooth and encapsulated. Most tumors are <3cm in 
diameter. 
C/s: grey to pink appearance often with sometimes cystic spaces can be seen. 
Membranous types are more often multinodular or multifocal.  
MICROSCOPY: BCA shows small cells with scant cytoplasm with peripheral 
palisading giving a  basaloid appearance . Polygonal basaloid   cells with slightly 
more eosinophilic cytoplasm in tumor center which are arranged in  trabeculated , 
tubular,  membranous pattern and solid pattern.  
The    presence of ductal lumina among the basaloid cells are considered as tubulo- 
trabaculae type .The membraneous and trabecular type  have a “jig-saw puzzule 
appearance”. 
Squamous differentiation  in the form of whorls or eddies, cystic change and 
rare cribriform pattern are common. Tubular type are rarely oncocytic . 
               In adenoid cystic pattern multiple pseudocystic formation may sometime 
be observed in basal cell adenomas in which dilated lumina usually contain Alcian 
blue positive material. 
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IHC:1) CK positive in luminal and abluminal cells in all tumors 2)EMA: expressed 
in all tumors in apical portion of luminal cells. SMA, calponin, p63, S-100 are 
strongly expressed in spindle shaped stromal cells. 
     DD: 1)PA, 2)AdCC, 3)Canalicular Adenoma 
Prognosis: 25% of membranous type have recurrence. Rare malignant 
transformation of BCA can occur. 
WARTHIN’S TUMOR:  was first reported by Hildebrad in 189538.It is   
composed of oncocytic epithelium and bilayered columnar cells that form multiple 
cysts. Sometimes accompanied by numerous papillary proliferation of follicle 
containing lymphoid follicle. 
Synonym: 1)Adenolymphoma 2)papillary cystadenoma lymphomatosum. 
EPIDEMIOLOGY: 2nd commonest benign parotid gland accounting 4-25% of all 
salivary gland. 5-7.5% of Warthin’s are bilateral.33,34.  Due to increased risk of 
smoking in females, the male predominance has now reduced to a 1.1:1 and 1.6:1.  
AGE: Average 62yrs. 
ETIOLOGY: Arise from trapped intraparotid or periparotid lymphoid tissue, 
intranodal occurrence suggest the possibility of multicentric growth. Smokers are at  
risk of eight times developing Warthin’s compared to non smokers. 
       Gallo O et al 1997 stated  that warthins is associated  higher incidence of 
autoimmune disease. 
CLINICAL PRESENTATION: Size: 2-4cm, Duration : 21month, pain 6% of 
cases,  painless fluctuant swelling in the lower part of parotid.  Technetium 99m 
Pertechate concentrates in Warthin’s tumor. 
GROSSLY : Well circumscribed ovoid to spherical mass.  
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CUT SURFACE: Number of cysts with filled with  brown viscous  fluid or 
caseous debri. Between cystic areas  minute tan to white nodular foci are seen. 
Coagulated content of cyst leave a rubbery consistency. 
 
HISTOPATHOLOGY: 
Tumor is sharply demarcated from surrounding parenchyma.It shows a cystic or 
epithelial  bilayered lining with  oncocytic features. The  epithelium overlies a dense 
lymphoid component that forms germinal centers. PTAH(Phosphotungistic acid 
hematoxylin)  demonstrate the granularity due to abundant mitochondria. Mucous, 
squamous or sebaceous cells are sometime seen. Mantle zone and germinal centers are 
found in more than half of cases.  
IHC: CK- positive in luminal and basal epithelium. p63 stains the basal cells. No 
dominant B or Tcell clonal population are present.  
Prognosis: 2% or less reccurence. Some recurrences are multifocal. 
DD: salivary gland lesion with papillary oncocytic epithelial component. 2)  
Epithelial lesion with abundant lymphoid tissue. 4) Lymphoepithelial cyst. 
 
ONCOCYTOMA (syn:Oxyphil Adenoma, Mitochondrioma, Oncocytic adenoma). 
Hamperl et al defined it as benign tumor composed of large granular, eosinophilic 
polygonal cells with numerous atypical cytoplasmic mitochondria. Neoplastic 
transformation of oncocytic duct epithelium and acinar cells is considered to be the 
cell of origin   
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EPIDEMIOLOGY: occurs in elderly patient. No sex predilection but clear cell 
type is common in females.. Oncocytomas constitutes about 1% of salivary gland 
epithelial neoplasm. More common in   parotid gland(80%).  Exposure to radiation  
is seen  in 20% of patients as reported by   Brandman38 et al. 
 
CLINICAL FEATURES: Present as small firm slow growing nodular painless 
swelling sometimes bilateral in parotid.39 
Gross : Firm, circumscribed, round to ovoid with slight lobulation. 
C/S :  Pink and uniform 
MICROSCOPY: Composed of  light oncocyte  with small number of   pyknocytic  
cells  arranged in nest, trabeculae, sheets and duct like structures. occasional clear 
cells due to margination of mitochondria and intracytoplasmic glycogen can 
occur12. Rarely FNAC site produces squamous metaplasia. The clear cells stain 
with PAS and tumor cells stain typically with PTAH. 
IHC: Immunoreactive for CK and antimitochondrial antibody.  
Prognosis : Recurrence is rare. when it recurs it present as bilateral and multiple 
nodule. The incidence of bilaterality is 7% 
DD :  
1) Acinic cell carcinoma,  
2) clear cell carcinoma,  
3) MEC with prominent clear cell with alteration,. 
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CANALICULAR ADENOMA:12,13,15 Benign, epithelial neoplasm,  composed of 
interconnecting cords of columnar epithelium in an extremely loose stroma  
 
EPIDEMIOLOGY : Occurs more common  in female in 7th decade of life and 
constitutes 2% of all salivary gland neoplasm. 10% in palate, 16% in buccal mucosa 
80% occur in upper lip.  
 GROSS: well circumscribed,tan to pink with solid or cystic cut surface.   
 
HISTOPATHALOGY:shows tubules or strands of columnar epithelial cells 
situated opposite to each other .The epithelial  cells are  cuboidal to columnar with 
eosinophilic cytoplasms.  Stroma is loose that appears to be “floating in the air”13. 
IHC : Shows immunoreactive for S-100 protein,CK7, CK8, CK13, CK14, and 
CD117. 
 
SEBACEOUS ADENOMA10,12,13,15. 
These tumors are  rare occurs  between 60-80 years of life,the commonest being  
parotid . 
CLINICAL PRESENTATION : Size <3cm in diameter. Asymptomatic, firm to 
hard, slow growing mass. 
GROSS:  Cystic, circumscribed and white to yellowish in color. 
HISTOPATHOLOGY:  composed of  cuboidal, basaloid, squamous and columnar 
cells arranged in island and small to medium sized cystic ducts that have numerous 
nests of sebaceous cells.  Mucous,oncocytic  metaplasia occur rarely 
DD: 1) sebaceous adenocarcinoma, 2) Lymph adenocarcinoma . 
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SEBACEOUS LYMPHADENOMA  
Age: 6th-8th decade, 90% occur in parotid, very rarely benign tumor. 
Gross: Shows solid,yellow to grey multicystic or unicystic encapsulated  mass 
.Sebum is found in many cysts. 
MICROSCOPY: sebaceous glands of various sizes are surrounded by abundant 
lymphoid stroma. Foreign body reaction may present occasionally. 
 
DUCTAL PAPILLOMAS: Rare benign salivary gland tumors arise from 
excretory ducts or junction between ductal and mucosal epithelium characterized by 
papillary growth. They are divided into 1) sialadenoma papilliferum, 2) intra ductal 
papilloma 3) ) inverted ductal papilloma. 
SIALADENOMA PAPILLIFERUM: 
Age: 59yrs M > F. Podoshin et al described this lesion in a 35yr old women in 
parotid gland. 
MICROSCOPY: Shows papillary process with convoluted clefts and spaces in 
between. Fibrovascular core are covered by parakeratotic, acanthotic stratified 
squamous epithelium. Double layer columnar to cuboidal epithelium cells overlies 
basal cuboidal cells. Chronic inflammatory infiltrate are frequent. 
IHC: Luminal cells are positive for pancytokeratin. CK7, CK18, CK19,  S-100 
protien  and EMA .  S-100 protien, CK7, CK14  are reactive for  basal ductal cells.. 
 
INVERTED DUCTAL PAPILLOMA: White and collegues in 1982 described 
this and it occurs in age group 30-60 yrs. Mean age is 60yrs. Both sexes are equally 
affected. The common sites are the minor salivary glands. 
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GROSS: Arise from the excretory duct of salivary gland and resembles 
sialadenoma papilliferum. They won’t produce papillary fronds and may produce 
budding of mucosa.  
MICROSCOPY: shows well circumscribed tumor mass within lamina propria and 
has an epidermoid appearance. 
INTRA DUCTAL PAPILLOMA: occurs in minor salivary glands. Age : 29-
77yrs. Mean age : 54yrs, equal sex ratio. 
Gross: show cyst wall with partially or completely filled with friable tissue 
MICROSCOPY : Papillary proliferation of bland columnar to cuboidal epithelial 
cells. It has a fibrovascular core that protrude into dilated cystic space40. 
CYSTADENOMA : Benign neoplasm characterized by adenomatous proliferation 
with formation of multiple cystic spaces lined by papillary projections. 
Mean age: 8th decade, equal prevalence among male and female. 65% cases occur 
in major salivary, remaining 35% cases occur in minor salivary glands 
GROSS : Tumor is well circumscribed with cystic spaces. 
Microscopy : Encapsulated, well defined tumor with multicystic spaces. Epithelial 
lining may be flat, columnar or cuboidal. Oncocytic and mucus changes of lining 
epithelium may exist. Cell lining the cyst may produce papillary projection with 
central cores of connective tissue41. 
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MALIGNANT TUMORS: 
MUCOEPIDERMOID CARCINOMA[MEC]:10,11,13.  Malignant epithelial 
glandular neoplasm characterized by intermediate, epidermoid cells and mucous 
cells. This account for 2-16% of all salivary tumor. Stewart et al in 1945 first 
described this as epidermoid tumor. MEC  is unique that it exhibit various spectrum 
from indolent to aggressive course  that are prone to recurrence, metastasis and 
local invasion43. 
AGE DISTRIBUTION: 3rd – 6th decade with mean patient age of about 45yrs. In 
children it account for the most common malignant gland tumor. Most of them are 
low grade with slight female predominance of 3:2 female to male ratio.42      
       Parotid being the most frequent site. Palate is the most frequently involved 
minor salivary gland site. Radiation exposure is the most common etiologic factor 
associated with development of MEC. It also reported in patient after radiation 
treatment for leukemia, lymphoma, sarcoma or thyroid Carcinoma. 
            Gross: Circumscribed but incompletely capsulated or unencapsulated firm 
mass. High grade tumor have infiltrative borders often with fixation to adjacent tissues. 
Cut section reveals cystic structures accompanied by grayish white to tan solid 
areas. Size ranges from <1cm to over 12cms. In minor salivary gland the size measures 
about  5cms. 
MICROSCOPY: MEC is composed of varying proportion of mucous,intermediate and 
epidermoid(squamous) cells.  Intermediate cells  are predominate with size between 
basal cells and epidermoid cells. Epidermoid cells have vesicular nuclei,open chromatin 
and abundant eosinophilic cytoplasm  Occasionally individual cell keratinization or 
keratin formation are seen. 
  
40 
 Mucocytes will take up the stains of mucicarmine and Alcian blue.They occur singly 
or in clusters cells, with a well defined cell membrane and  foamy Cytoplasm.  The 
intermediate, epidermoid and clear cells usually predominant in high grade with high 
reccurence rate and cervical lymph node metastasis. The low grade have predominantly 
cystic  with few tumor cells. 
             Griddin et al reported sclerosing variant characterized by an intense central 
sclerosis44. some clear cell MEC’s are associated with extensive intratumoral 
calcification48 Some cases of MEC shows melanin pigmentation49 
Special stain: Mucous cells are large and have pale to slightly basophilic fine 
cytoplasm with positive reaction to PAS, Alcian blue and mucicarmine stains.  
Various grading system are suggested by different authors. WHO in its 2nd edition 
divided this tumor into two grades – well differentiated or low grade tumor and poorly 
differentiated or high grade. The 3rd edition WHO’s grading system divides MEC into 3 
grades15. 
Histopathologic features Point value 
Neural invasion +2 
Cystic component <20% +2 
4 or more mitosis/10 HPF +3 
Necrosis +3 
Anaplasia +4 
 
Grade of tumor score 
Low 0-4 
Intermediate 5-6 
High 7 or more 
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GENETICS : 
  t(11,19) ,(q21,p12-13) translocation is frequently seen in MEC.. 
 Molecular analysis demonstrates fusion transcript between MECT1 (Mucoepidermoid 
carcinoma translocation1) with MAML2 (master mind gene familyL2).This fusion 
transcript act as a co-activator for notch receptor transcriptional activation and 
signalling.10,22  This translocation is frequently associated with low grade histology.  
IHC:13,20,52 Most tumor cells are positive for Pan- cytokeratin. Variable staining for 
EMA, CEA, and S-100. p63 staining is demonstrated in squamous and intermediate 
cells . 
MUC1 and MUC4 are expressed by normal ductal cells.  
MUC5B taken by acinar cells which have cytoplasmic mucin.   
In high grade MEC, MUC5AC expression is high which helps to differentiate it 
from Squamous cell Carcinoma 
High MUC1expression is correlated with high recurrence ,metastasis and short 
survival rate  
High MUC4 is associated with low grade tumor, low recurrence rate and long 
survival rate . Hence MUC4  is used in tumor differentiation grade.52  
In contrast to Squamous cell Carcinoma MEC often express CK7 and negative for 
CK20. 
 
PROGNOSTIC FACTORS: Behavior of MEC is strogly correlated with clinical stage 
and histologic stage. Cure rate is high in low and intermediate MEC. Mayo clinic study 
shows that grade and stage are less important if radical surgery is performed.45  
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Tumor is considered to have low radio sensitivity. High proliferative 
index(mitotic count >2/10 HPF) or Ki index > 10%, expression of MUC1, vascular 
invasion, involved margin are associated with poor prognosis. 
DD :  1)Warthin’s tumor with squamous/mucinous metaplasia 2)Pleomorphic adenoma 
with squamous differentiation 3)poorly differentiated adenocarcinoma  4)Squamous 
cell Carcinoma. 
 
ADENOID CYSTIC CARCINOMA[AdCC]10,11,13,20 
 Definition : It is an aggresive type composed of basaloid cells with myoepithelial/basal 
cell differentiation admixed by ductal structures. It is characterized by tubular, 
cribriform or solid pattern of growth and a myxohyaline stroma. Adenoid cystic 
Carcinoma is encountered from 1-9th decade of life. 
F:M Ratio is 3:2, higher incidence in 40-60yr of life. 42% arise from major salivary 
glands. 68% from minor glands. Most common site were parotid(21%), palate(17%), 
submandibular gland(13%) and it account for 10% of salivary epithelial neoplasm. 
Billroth first described Adenoid cystic Carcinoma in1859. The term cylindroma was 
used until Frozell and Foote in 1953 expressed their preference for Adenoid cystic 
carcinoma. 
In 1971 Hubner et al said that Adenoid cystic Carcinoma originate from myoepithelial 
cells claiming that acellular hyaline material is the product of myoepithelial cells. 
In 1986, Chaudhry et al after their ultra structural of 12 cases suggested the origin from 
acinar- intercalated junction in the intercalated ducts proper46. 
Gross : Tumor is fleshy, firm, tan and invasive. Perineural invasion is very common.  
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Three characteristic growth pattern are defined, 
1)   Cribriform  pattern is the most frequent pattern observed,  composed of two 
main types 1) Ductal 2) Myoepithelial cells with microcystic  spaces.  They 
have typical hyperchromatic angular nuclei  with clear cytoplasm. They have 
propensity to involve the peripheral nerves47.They are PAS +ve for hyaline or 
basophilic mucoid pattern. 
2) Tubular pattern  shows luminal layer of epithelial and outer layer of 
myoepithelial cells , characterized  by well formed  tubules and ducts  with 
central lumina 
3)  Solid or basaloid types  shows sheets of uniform basaloid cells but  lacks 
tubular or microcystic formation. 
Perzin et al in 1978 concluded that in soid  type  prognosis is poor with high incidence 
of metastasis and rapid clinical course. The cribriform pattern has intermediate 
prognosis and tubular pattern having best prognosis.  
Paulino AF et al studied 29 cases and stated that AdCC characterized by infitrative 
capacity and propensity for neural invasion. Facial nerve palsy and large area of tumor 
necrosis are bad diagnostic signs. Dedifferentiation can also occur in Adenoid cystic 
Carcinoma,50 such cases caries very poor prognosis. Brain derived neutrophilic factor is 
a growth factor involved in neurogenesis and is uniformly expressed51. 
HISTOCHEMISTRY: The luminal spaces with eosinophilic  hyaline material take  up  
PAS/Alcian blue. 
IHC :Ductal  lining  cells  are positive  for C-Kit.  Epithelial cells are variably positive 
for it markers such as CK, CEA, EMA.  Myoepithelial cells will stains for  p63,  
Calponin, S-100.  GFAP positivity  suggest neural invasion and late distant metastasis. 
Ki-67, C-Kit  help to differentiate between PLGA and AdCC. 
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Prognostic factors: large size >2-4cm, minor glands, High Ki67 index shows poor 
prognostic factor. 
 
ACINIC CELL CARCINOMA[ACC]10,11,13. 
Definition : It is a neoplasm demonstrating at least focal differentiation towards serous 
acinar cells. Buxton et al in 1953 were the first to describe the term serous cell 
adenocarcinoma. Tumors constitutes 4-6% of all salivary neoplasms. 
Commonest site : Parotid and minor percentage found in submandibular and minor 
salivary gland. Rarely parapharyngeal spaces,53  pancreas and lung. 
In 2002 Hwei-Yee,et al a primary ACC of lung with regional lymph node 
metastasis and perineural invasion.54.    
Age : 3rd –7th decade. Mean age is 44yrs. Second  most common malignancy in 
children. Female predominance has been observed. 
Gross : Well circumscribed encapsulated mass with a diameter of 2-4cm. Grey white to 
reddish gray on cut section. Consistency varies from firm to soft. Most of the tumors 
are solid and cystic tumors. 
Microscopy: These  tumors  shows  acinar cell differentiation with  zymogen granules 
in cytoplasm.  Pattern of growth varies from solid microcystic, papillary cystic, 
follicular, tubule ductal or dedifferentiated and non specific glandular.   A delicate 
fibrous pseudocapsule and psammoma body like calcification and a may seen in some 
tumor.  
CLASSIC ACC OR THE SOLID VARIANT: Shows well differentiated serous 
acinar cells with basophilic to gray granular  in the cytoplasm. PAS +ve and 
mucicarmine –ve zymogen granules  are seen in the cytoplasm.  In high grade 
malignancy vascular and neural invasion are seen.  
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PAPILLARY- CYSTIC VARIANT: Rare variant characterized by large cystic spaces 
which are lined by stratified cuboidal or simple epithelium with some papillary 
projection. The papillae are covered by hobnail cells,  intercalated duct like cells, 
vacuolated cells and non descript variant cells which posses eosinophilic to 
amphophilic cytoplasm, central nuclei  and indistinct cell borders.  
 
FOLLICULAR VARIANT: Closely packed round cystic spaces filled with 
homogenous eosinophilic colloid- like material highly reminiscent of thyroid follicles. 
The colloid materials are PAS +ve.  
 DEDIFFERENTIATED ACINIC CELL CARCINOMA:  Associated with rapid 
tumor growth, facial pain, bulky tumor and extremely poor prognosis. Usually present 
with areas of poorly differentiated  adenocarcinoma NOS type. Extensive oncocytic 
change has rarely reported.55 
IHC: Acinar cell and ductal cells are  positive for CK, CEA, amylase. 
DOG(discovered in GIST) – recently shown to be in acinar cell markers.56 Prognostic 
factors  clinical stage and resection margin status are important prognostic indicators. 
Simpson et al57 suggest that dense lymphoid stroma with germinal centre and 
microcystic growth pattern have particularly favourable prognosis. 
 
POLYMORPHOUS LOW GRADE ADENOCARCINOMA10,11,13,15.  
In 1984 Batsakis and Evans first described this carcinoma. WHO classification of 
salivary gland tumor adopted the term polymorphous low grade adeno carcinoma. 
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CLINICAL FEATURES :  The palate is the  most common site(60-70%), followed by 
buccal mucosa (16%) upper lip (12%) retromolar area, base of tongue rarely lacrimal 
gland. Peak age is in 5th-6th decade. F>M, present as asymptomatic mass with or 
without ulceration. 
GROSS : Circumscribed, non encapsulated, tan to gray masses with glistening cut 
surface with infitrative margins. Size 0.4-6cm  with average of 2.2cm. Perineural 
invasion is common.  
MICROSCOPY: Tumor has polymorphous growth architecture showing 
predominantly solid, tubular, fascicular and cribriform foci of squamous are mucinous 
metaplasia  or with areas of papillary change are found.58  The  tumor cells have round 
pale nuclei with  fine evenly spaced chromatin and indistinct nucleoli. The tumor cells 
always maintain bland cytological features with cuboidal, spindled or polygonal shapes. 
Mucinous or clear cells are occasionally seen. Myoepithelial cells are absent or 
at most present very focally at the light microscope level. Stroma is slight grey blue and 
is said to be characteristic. Psammoma bodies and collagenous or tyrosine type 
crystalloids are found in some cases. 
Dedifferentiation to high grade salivary duct carcinoma with predominantly 
solid and cystic growth, high nuclear grade, obvious tumor necrosis present. 
IHC:19,20  Positive for low and high molecular CK, EMA. Strongly and diffusely 
positive for S-100 protein. Some but not all  PLGA are also positive for myoepithelial 
markers. Ki67 index for PLGA is 6.4% when compared to 54% of high grade Adenoid 
cystic carcinoma help to different both. 
AdCC were strongly positive for C-Kit but only  small percentage shows positive for  
PLGA 
DD : 1) PA  2) Adenoid cystic carcinoma. 
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EPITHELIAL-MYOEPITHELIAL CARCINOMA (EMC)10,11,15.  
Donath and colleagues in 1972, first described this carcinoma. Rare tumor 0.4% of 
salivary gland neoplasm. Peak incidence : 6th-7th decade. 60% percent occurs in parotid. 
 
CLINICAL FEATURES : Asymptomatic mass. Patient present with  pain and facial 
weakness. It is a low grade tumor with recurrence of 30-40%. Regional metastasis 
occurs in 10-20% of cases. Distant metastasis to kidney, lung and brain is uncommon. 
Gross : Well defined swelling, nodular or multi nodularity 1/3rd cases are encapsulated. 
Cut surface  shows grey yellow to white  with cystic areas.  Tumor measures 2-8cms in 
diameter with mean 3cms. 
 
MICROSCOPY : EMC is characterized by double layered, duct like structures lumid 
cells are arranged as single cuboidal or columnar luminal cells that have a central round 
or oval bland looking nucleus with moderate amount of pink cytoplasm. Rarely 
extensive squamous, sebaceous or apocrine differentiation can be present. Perineural 
and vascular invasion are common . Moderate to severe degree of nuclear atypia is seen 
in dedifferentiated tumor.   
Special stain in EMC : Clear cell components  contain abundant glycogen which 
shows  PAS positive material . 
IHC: Ductal cells are positive for Pan-CK, variably stain  for S-100 protein but 
do not take up the myoepithelial markers. Abluminal cells are positive for p63, S-100 
protein, calponin and actin. Proliferative index is low <1% for ductal cells and <3% for 
abluminal cells. 
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DD : Distinguished from other clear cell tumors with double layered as duct like 
structure. 1) Pleomorphic adenoma. 2) Tubular variant of AdCC. 3) Mucoepidermoid 
carcinoma 4) Acinic cell carcinoma. 
PROGNOSIS : Marginal status is the most significant pathologic prognostic factors.  
Poor prognosis is seen in tumors located in minor salivary and seromucinous glands 
because of high frequency of recurrences. 
 
SALIVARY DUCT CARCINOMA 
In 1968 Kleinsasser et al first described  salivary duct carcinoma. 
Definition : Aggressive malignant tumor morphologically resembles high grade ductal 
carcinoma.  
Clinical features : Age : 6th- 7th decade. Sex M : F = 3 to 6 : 1. Parotid account for 
80% of cases. Patient present with rapidly growing parotid mass associated with facial 
nerve palsy (42%), pain (23%) and 35% shows cervical lymphadenopathy. It is the 
most aggressive  tumor with a mortality rate of 77%. They account for 2% of salivary 
neoplasms. 
Gross : Unencapsulated,solid,  highly infiltrative grey to white with rare areas of cystic 
change and foci of necrosis. Size : 3cm. 
MICROSCOPY : Infiltration into soft tissue and adjacent gland is evident. 
Histologically mimicks high grade ductal Ca of breast with mixture of two components 
 INTRA DUCTAL : consist of large ductal structures with various 
pattern   1) cribriform, 2) papillary and 3) solid growth pattern.  
                        cribriform carcinoma: may form tumor cells arches in relatively large 
intercellular spaces called ‘roman bridge architecture’. Comedo necrosis is common in 
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the central portion of ductal cells. Psammoma bodies and  focal squamous 
differentiation, some with keratinization can be seen in tumor nests cells. 
 INVASIVE COMPONENT : shows irregular cords and glands that 
frequently shows desmoplastic reaction. SDC with pure intra ductal or 
minimally invasive form associated with better prognosis.  Neoplastic 
cells have apocrine appearance with abundant eosinophilic cytoplasm, 
large pleomorphic vesicular and prominent nucleoli. Stroma densely 
fibrous or desmoplastic, perineural invasion, intravascular tumor emboli 
are common. 
 
Variants of SDC : 
1) Sarcomatoid variant(Dedifferentiated salivary duct Ca):82,83Composes of 
anaplastic spindle cells, multinucleated giant cells, rhabdoid cells, 
osteosarcomatous cells. This is consider as a dedifferentiation of  salivary duct 
Carcinoma. 
2) Mucin rich variant:84  Clusters of carcinoma cells float in a area of mucin or 
colloid. 
3) Invasive micro papillary variant:85. Shows morule like tumor cells  with 
absence of fibrovascular cores surrounded by clear space morphologically 
similar to micropapillary variant of breast . 
4) Oncocytic variant : Abundant eosinophilic granular cytoplasm and strongly 
immunoreactive with anti mitochondrial antibody. 
Prognosis:  Brandwein et al stated that Size <3cm are  have good prognosis.88 
Histologically   micro papillary pattern are more aggressive. Lymph node metastasis 
and positive surgical margins associated with less survival rate. 
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IHC : Tumor cells shows diffuse strong staining for CK, EMA and CEA. 
Fan CYet al in 200086 stated that almost all cases express Androgen receptor, ER/PR 
are usually negative. HER-2/neu  over expression is associated with worst prognosis. 
Some cases shows prostatic acid phosphatase, prostatic specific antigen or CK20. Ki-67 
index is high (mean 21.3%). 
Laforga et al  in 2004 reported a single case with neuroendocrine differentiation87.  
Genetic : Loss of heterozygosity is detected  in 9p21, 6q, 16q, 17p gene. Mutation and 
over expression of TP53 gene and protein are frequent. HER2 gene amplication occur 
in 12-36% and over  expression in 26-100% of cases. Gene expression profiling stated 
by Leivo et al in 2005 stated overexpression of apoptosis related gene 
CASP10[Caspases-10] and MMP11[matrix metalloprotein-11] in SDC.89  Tumor 
progression is associated with inactivation of CDKN 2A/p16 gene.[Cyclin Dependent 
Kinase inhibitor 2A].  
DD : 1) Metastatic breast / prostatic Ca 2) High grade MEC 3) Oncocytic Carcinoma 
 4) Cystadenocarcinoma 5) Intraductal Carcinoma. 
 
INTRA DUCTAL CARCINOMA. 
 Synonym: Low-grade salivary duct Ca/low grade cribriform  cystadeno Carcinoma. In 
1983 Chen first described intraductal Carcinoma, later it was defined as tumor of low 
malignant potential similar to mammary counterpart90.  
Clinical features : Frequently affects the parotid (mean age of 62yrs) with slight 
female predilection. Minor salivary gland ( palate, tongue,and oral cavity) can be  
affected. 
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MICROSCOPY : Smooth-contoured ducts with epithelial cell proliferation forming 
solid–comedo, cribriform, micropapillary or Roman bridge pattern similar to salivary 
duct Carcinoma. Focal invasion into surrounding tissues is seen. 
 
CLEAR CELL CARCINOMA : not otherwise specified10,11,13.. 
 Malignant epithelial tumor occurring in 40-70yr of age. Frequently occur in 
minor salivary glands, clinically with mucosal ulceration and pain. 
Gross : <3cm, poorly circumscribed, infiltrating into adjacent mucosa, soft tissue, bone 
and nerves with grey white on cut section. 
Microscopy : Composed of nests and cords , sheets of monomorphous polygonal to 
round cells with clear cytoplasm and is characterized by absence of features 
characteristic of any other salivary gland tumor with clear cell change. Prognosis is 
excellent. 
 
BASAL CELL ADENOCARCINOMA. 10,11,13,15. 
 Low grade malignant neoplasm with cytological resemblance to basal cell 
adenoma. Diagnosis is confirmed with demonstration of infiltration of surrounding 
salivary lobules, nerves or blood vessels occur in average age of 60yrs with no sex 
predilection. 
Arise de novo in the parotid gland less commonly of submandibular gland, oral 
cavity and upper respiratory tract91. In 23% of cases it arise from basal cell adenoma 
particularly the membranous types or monomorphic adenoma. 
Gross : Most occur in superficial lobe of parotid gland. Cut surface is grey, tan white 
or brownish unencapsulated but may be well circumscribed but usually infiltrative. 
Size : 0.7 – 7cm. 
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Basal cell adenocarcinoma has predominantly solid pattern,characterized by  islands of 
tumor cells,  areas of  basaloid cells with peripheral palisading. 25 to 33% of these 
tumor may show intravascular and perineural invasion.92 
IHC : Tumor cells are reactive for CK and locally reactive for S-100, EMA. 
 
MALIGNANT SEBACEOUS TUMORS. 10,13,15. 
1) Sebaceous carcinoma : In 1966, Goldstein and silver first described  
as a rare primary carcinoma of salivary glands. Bimodal age distribution 
between 3rd and 7th decade. No sexual predominance. Usually present as 
painless mass with perineural invasion and majority of them occur in 
parotid gland. 
Gross : Size : 0.6 – 8.5cm. Color varies from tan white, grey white to pale pink 
well circumscribed or partially encapsulated with pushing or infiltrative 
margins. 
Histology : Tumor is composed of nests or sheets of sebaceous cells of varying 
maturity, different degree of polymorphism, nuclear atypia and 
invasiveness. Squamous and basaloid differentiation are common, with 
perineural invasion is seen in 20% of cases93. 
2) Sebaceous lymphadenocarcinoma:  Rarest salivary gland sebaceous tumor 
with only 5 cases reported in the literature93. 
Age : Occur in 7th decade, arise in parotid or in periparotid lymph node. 
Gross : Yellow tan  to grey colored. Partially encapsulated with areas of  
invasive foci 
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Microscopy: composed of typical sebaceous lymphadenoma intermixed 
with or adjacent to regions of pleomorphic carcinoma cells exhibiting 
varying degree of invasion. 
 
 
CYSTADENOCARCINOMA:10 
Most of the patient are over 50yrs of age, 65% occur in major salivary gland as 
a slow growing, compressible asymptomatic mass. 
Gross : numerous cystic spaces of varing  sizes  filled with mucin. 
Microscopy : Well circumscribed,  shows  predominantly cystic growth  with  
intraluminal, papillary pattern.15 
ONCOCYTIC CARCINOMA3,11. : In 1953, Bauer described the first case. 
Constitutes < 1% of all  salivary gland tumors. Males are affected in 2/3rd of cases.  
Age : 25 – 91yrs with mean age of 62.5yrs. 80% occur as painless mass. 
Gross : Unilocular or multilocular masses. Unencapsulated tan to grey, some cases   are 
focally necrotic.   
Microscopy:  Cells shows variations in size, shape and nuclear pleomorphism. 
Minimal nuclear atypia. Tumor cells form nests or ducts, trabeculae, sheets that 
infiltrate salivary gland parenchyma and surrounding tissue. Perineural and vascular 
invasion can occur.  
High Ki-67 help to differentiate it from oncocytoma. 
 
ADENOCARCINOMA, NOT OTHER WISE SPECIFIED : It refers to primary 
carcinoma of salivary gland which exhibit glandular differentiation but lacks diagnostic 
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criteria of other tumor categories. Occurs in elderly.  Peak age 6th -8th decade of life 
with male preponderance. 
Site : Parotid gland, submandibular gland, palate  and buccal mucosa. Facial nerve 
involvement is common. Tumor involving oral cavity carries favourable outcome than 
that of parotid   or  submandibular gland. 
Gross : Firm, infiltrate and partially circumscribed with areas of haemorrhage and 
necrosis. 
MICROSCOPY : shows ductal or glandular differentiation with invasion into adjacent 
salivary gland parenchyma. It lacks any of the histomorphologic features of other 
recognised  salivary gland adenocarcinoma. Most adenocarcinoma NOS  are considered 
to be high -grade histologically. 
Immunohistochemistry: positive for pan–cytokeratin . 
MYOEPITHELIAL CARCINOMA :Rare neoplasm occuring in elderly is composed  
predominantly of  tumor cells with myoepithelial differentiation   with tendency for 
metastasis and infiltrative growth. Clinically present as destructive tumor with pain or 
painless mass. 
 
CARCINOMA EX PLEOMORPHIC ADENOMA10,13,15[CaexPA] :  
In 1957, Bearhrs et al first described carcinoma ex pleomorphic adenoma. 
Definition : Carcinoma  that arise from epithelial or myoepithelial component of 
pleomorphic adenoma.  
        M.sherif et al in 2013 stated that ca ex PA constitute 99% of all cases of malignant 
mixed neoplasms. It develops in 6% of all PA and constitutes 3.6 – 4% of all salivary 
gland neoplasms.. Occurs in 6th -7th decade of life. Median age of onset : 10 – 20yr 
older than patient with PA.  
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Hu et al suggests that  p16 gene methylation may be responsible for evolution of PA to 
ca ex PA.94 
Bassel Tarakji et al 95(2010) stated  that inactivation  of  p53 play a important role in 
evolution of Caex PA.  Eiji Mitate et al 2013 reported a case of an unusual malignant 
component of squamous cell carcinoma96. 
GROSS: poorly circumscribed and infiltrative masses to completely encapsulated 
appearing masses. 
MICROSCOPY:  The PA  component was represented by scarring, the malignant 
component shows features of SDC,poorly differentiated carcinoma NOS type.  
Genetic studies : Amplification and over expression of gene 12q13-15 including CDK4,  
HMG1C and MDM2 are important events in malignant transformation. HER2/neu over 
expression occur in 21–82% of cases. Altered p53 gene are found in 29-67% of cases 
and p53 over expression  seen in 41 -75% of cases suggest that may play a role in 
transformation.65,67  
Ki -67 proliferative index is increased compared with PA. S100, Her2/neu help to 
differentiate carcinoma ex pleomorphic adenoma from atypical PA65,67.. 
 
CARCINOSARCOMA10,11,13 : Rare malignant tumor of salivary gland composed of 
combination  sarcomatous and carcinomatous  elements. It occurs in elderly as painful 
mass. Parotid gland is involved in 2/3rd of cases. 
GROSS : Poorly circumscribed mass, occasionally tumors are partially or totally 
encapsulated. 
Cut section : Greyish in color with yellowish area of necrosis and haemorrhage. 
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MICROSCOPY: The commonest sarcomatous elements are Osteosarcoma and 
chondrosarcoma. Ductal carcinoma is the most common carcinomatous element and 
they are treated with wide surgical excision. 
 
METASTASING PLEOMORPHIC ADENOMA13 : Rare complication of PA with  
metastasis occurring after 1.5 – 51yrs. 40 cases have been reported so far. 3/4th of cases 
occur in parotid gland. Metastatic tumors retains the benign histologic feature of 
pleomorphic adenoma. Common metastatic site are 1) bone (50%), 2) lung (30%) and 
3) lymph node (30%). Scalp, abdominal wall and liver metastasis have been reported97 
 
SQUAMOUS CELL CARCINOMA10,13 : It arises from squamous metaplasia of 
salivary duct. 80% of cases occur in parotid of age group 7- 65yrs. 
GROSS : unencapsulated, poorly demarcated, firm to hard in consistency.  
CUT SURFACE: grey or white  
MICROSCOPY : Similar to squamous cell carcinoma ranging from low grade, highly 
keratinized neoplasm to poorly differentiated sheets of tumor cells with minimal 
keratinization. Soft tissue invasion and regional metastasis are common 
DD :  1) High grade MEC, 2) Metastatic carcinoma, 3)Primary salivary gland 
Squamous cell Carcinoma.. 
IHC: Squamous cell carcinoma were negative for MUC5AC,CK-7,CK-20 these 
markers helps to distinguish high grade MEC from Squamous cell Ca60 which shows 
CK-7 positive and CK-20 negative.. 
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SMALL CELL CARCINOMA : Very aggressive  rare tumor account for <4% of 
major salivary gland tumor. These are common between 5th and 7th decade of life. 85% 
of small cell carcinoma arise from parotid and others from sub mandibular glands.More 
than half of  patients develop local recurrences or metastasis98.  
Gross : Tumors are poorly demarcated. They are firm to hard in consistency  
Cut section:  Variegated appearance  
Microscopy: shows proliferation of small pleomorphic cells with fine nuclear 
chromatin, inconspicuous nucleoli and with scant amount  of cytoplasm resembling 
small cell carcinomaof lung99,100. 
IHC : 73% of salivary gland small cell Ca express CK2099. 
 
LARGE CELL CARCINOMA: Rare tumor,occurring in parotid composed of  
pleomorphic cells with abundant amount of cytoplasm . 
 
LYMPHOEPITHELIAL CARCINOMA: It is an undifferentiated Carcinoma  
similar to morphology of poorly differentiated ca of nasopharynx.. High prevalence 
among Chinese population. Present clinically as mass in the cheek since birth.101 
SIALOBLASTOMA: Rare congenital epithelial tumor, Vawter and Tefft first 
described this case as “embryoma”in 1966 since then various names were used. It was 
locally invasive. 
MICROSCOPY: Shows basaloid cells with very few nucleoli with very few 
cytoplasm. 
IHC : CK positive in ductal component, Vimentin  in both ductal  structures  and solid 
nests.102 
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SOFT TISSUE TUMORS : 
Benign tumors: with exception of hemangioma, soft tissue tumors of salivary gland 
are very uncommon and mostly benign.they account for 1.4% of salivary gland tumor.  
Of this 30.5% are  neural tumors, 30% hemangiomas, 18.5% are fibrous, 9% lipomas, 
7% lymphangioma, 5% others. Hemangiomas and lymphangiomas occur during first 
three decade of life. 
 1)  Hemangioma : Soft tissue tumor constitutes of 0.4% of all salivary gland 
neoplasm. Most common age group of presentation is 2nd decade, composed of  
proliferation of pericytes and endothelial cells . 
2)Lipoma : uncommon benign soft tissue tumor involves parotid with incidence of 
0.5-2%  M : F ratio is 10 : 1. Subtypes like spindle cell lipoma, angiolipoma, and 
hibernoma have been reported. 
3)Lymphangioma : rare tumor usually occur in parotid. 
4)Neurofibroma and Neurilemmoma : It arise from one of the fine radicals of facial 
nerve. 
5)Sarcoma : they are very rare. Fibrosarcoma and malignant schwannoma are the 
commonest. In 1997, Shat et al report one case of intra parotid Schwannoma. 
   Lymphomas : It arise in salivary gland, very rare as the only manifestation or part of 
systemic disease. Most common are NHL type (85%) most NHL’s and B-cell 
lymphomas, follicular and extra nodal marginal zone B-cell lymphoma. 
SECONDARY TUMORS:10  Peak incidence 7th – 8th decade. It comprises 5% of all 
malignant tumor salivary gland tumors103. Majority occur in parotid followed by 
submandibular. Most frequent are small cell carcinoma followed by malignant 
melanoma. 84% of tumor that metastasize to parotid  originates in head and neck 
region. Other sites are lung, kidney, and breast.  
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                                    IMMUNOHISTOCHEMISTRY19,20. 
   ROLE OF IMMUNOHISTOCHEMISTRY IN SALIVARY GLAND  TUMORS    
Salivary gland tumors shows striking morphological diversity. Tumors contain 
various propotion of ductal/luminal cells and myoepithelial /basal cells. This provides 
the basis for immunohistochemical demonstration  of various  components. The main 
application of  IHC in salivary gland tumor is to demonstrate the existence of 
myoepithelial/basal or luminal component when diagnosis is uncertain. 
            Many immunohistochemical investigation uses differentiation  markers specific 
for myoepithelium.  Initially S-100,  vimentin ,and GFAP were used  but found to be 
non specific.  The most reliable marker currently used for neoplastic myoepithelial cells 
are p63,calponin and mapsin. 
 
MYOEPITHELIAL MARKER- p63. 
            p63 gene, a member of  p53 gene family play an essential role in epithelial   
development, stem cell identity cell and cellular differentiation.73 
It is expressed in atleast  six protein isoforms 70,71,76..They are divided into two 
groups. 
1. Those with transcription activation domain.(TAisoforms). 
2. Those without transcription activation domain(Delta N isoforms). 
           TA isoforms  are able to activate transcription  of specific target and induce cell 
cycle arrest and apoptosis.Studies on human tumor suggest an oncogenic  function for  
Delta N isoforms. 
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Foschini et al stated 71that the isoforms of p63 was present in the tumoral tissue 
but absent in normal salivary gland.This observation suggest that p63 particularly its 
isoforms, is involved in the neoplastic transformation of salivary glands. 
Weber et al73  [2002] stated  that in normal parotid tissue the expression of p63 was 
restricted to few basal and myoepithelial cells. Ductal,luminal,and acinus cells were 
completely negative Salivary gland tumors shows strong nuclear staining for p63,which 
suggest the role of p63 in oncogenesis of these tumors. 
Bilal et al 75   stated that p63 is retained in modified myoepithelial and basal cells of 
human salivary gland tumors ,which suggest the role of p63 in the oncogenesis of 
tumor complex. 
p63  is  positive in PA, basal cell adenoma, warthin’s tumor, PLGA ,epithelial-
myoepithelial  cell carcinoma  and myoepithelial cell carcinoma. 
Edward PC 72 stated that  p63 is strongly expressed in basal cell adenoma of parotid 
origin .  In Adcc  positive reactivity is observed in the non luminal  myoepithelial cells  
surrounding the luminal cells. In canicular adenoma  p63  staining was found to be 
negative.  p63 does not appear to be a ideal marker for distinguishing  Adcc ,PLGA,and 
basal cell adenoma  
 p63  is  also expressed  in squamous  epithelial cells,  and  basal cells, so care should 
be taken while evaluating them. 
Other myoepithelial markers: calponin ,α-SMA, S-100,Vimentin are  non  specific 
markers because they are also observed in ductal cells. They are only used for initial 
screening of  myoepithelial cells. GFAP has low sensitivity as a myoepithelial marker, 
but frequently detected in pleomorphic adenoma and myoepithelioma.   
Langham G et al65 stated WT1(Wilms tumor product) was recently reported as 
sensitive marker of neoplastic myoepithelial cells in pleomorphic adenoma. 
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Hence Panel of markers are used to investigate neoplastic myoepithelial cells. For cases 
with minimal number of section, screening with pan –CK,calponin, α-SMA, p63 and S-
100 protein is the best in terms of specificity. Normal myoepithelial cells serve as 
internal control for myoepithelial  markers.So, if possible  IHC should be performed in 
a section with normal salivary gland tissue. 
 
TUMORS WITH ONCOCYTIC AND SEBACEOUS  DIFFERENTIATION.65.: 
  Tumors with oncocytic differentiation such as warthin’s, oncocytoma, 
oncocytic carcinoma, ,Mucoepidermoid carcinoma are positive for antimitochondrial 
antibodies.   Tumors  with sebaceous differentiation such as sebaceous adenoma and  
carcinoma  are intensely positive for EMA. 
     McHugh J B et al 74(2007) stated that metastatic renal cell carcinoma in 
head and neck  often mimicks benign and malignant oncocytic  lesions. Expression of 
p63  in oncocytic lesions exclude metastatic RCC(Renal cell carcinoma) from the 
differential diagnosis  of these salivary gland lesion. 
 
DIFFERENTIAL DIAGNOSIS OF PROBLEMATIC SALIVARY GLAND 
TUMOR 
AdCC,SDC  exhibits cribriform structures ,  others in differential diagnosis  are 
PA,EMC,PLGA, Sialoblastoma. 
 α-SMA/calponin  positivity distinguish  AdCC and BCA which are  sometime 
challenging to diagnose by  histological examination alone. 
Ki -67 labelling index ≥10% in AdCC, whereas≤ 10% in BCA.  Presence of 
strong S-100 positive stromal cells support the diagnosis of BCA. 
Sialoblastoma are differentiated by early onset of age. 
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TUMORS OF BENIGN AND MALIGNANT COUNTERPART: 
Benign and malignant counterpart of salivary gland tumor shares similar 
histological features. Malignant counterpart is differentiated by perineural and   
vascular invasion, necrosis and mitosis. IHC assessment  of Ki-67 labelling index help 
to differentiate myoepithelioma ≤10% from myoepithelial carcinoma ≥10%. IHC 
markers for BCA and basal cell adenocarcinoma displays  a striking similarity so they 
are of little value in differential diagnosis. 
 Higher rate of cell proliferation(Ki-67≥5%). 
 Apoptosis index >0.4%. 
 p53-strong positive. 
 Loss of bcl-2 expression   
 Differentiates  basal cell  adenocarcinoma  from  basal  cell  adenoma.    These tumors 
may positive for HER-2/neu and high Ki-67 index. 
 
DIAGNOSIS OF SPECIFIC TUMOR TYPES:  
PLEOMORPHIC ADENOMA(PA): Luminal cells are positive for cytokeratins. In 
myxoid and solid areas neoplastic cells are positive for vimentin, S-100, GFAP, 
calponin and smooth muscle myosin. p63 shows positive in modified myoepithelial 
cells.  A recent study  of 45 cases of pleomorphic adenoma  revealed  that  all 45 were 
positive for PLAG1. PLAG1was also specific for CA ex PA against other tumors. 
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  C-KIT(CD-117) IN ADENOID CYSTIC CARCINOMA:19,20 
   C-KIT  :   A  transmembrane  receptor tyronine kinase, is negative in normal     
salivary gland, but more than 90% of cases of Adcc are positive for CD-117 [luminal 
cells]. Recent literature stated  that CD-117 is expressed in Adcc is not specific for 
Adcc59but the extent and intensity of staining exceeds other tumors.  
Holst VA78,79 et al stated[1999] that  gene mutation  of exon 11 or exon 17 is 
not a mechanism of  c-kit activation in these neoplasms. 
Carla  R Penner D.D.S.et al80[2002]study stated that  c-kit is expressed in ADcc 
but not in PLGA.  Expression of galectin -3 is significantly  expressed in PLGA but 
decreased in Adcc. 
Seethala RR,105et al [2004]study shows  CD43, a marker of T- cell and 
histiocyte tend to be localized in abluminal cells in a membranous pattern. Thus CD-
43 immunohistochemistry have some utility in supporting the diagnosis of Adcc in 
difficult  cases. 
 
MUCOEPIDERMOID CARCINOMA:(MEC) 
p63 expression is absent or minimal in mucoepidermoid carcinoma. MEC 
express membrane bound mucin such as  MUC1, MUC4, MUC5AC and MUC5B. 
            Handra –Luca A et al104 [2005] stated that MUC1 is associated with high 
histological grade, metastasis  and recurrence rate. MUC4 is associated  with tumor 
differentiation with low histological  grade, low recurrence. Positive  staining  for 
MUC5AC  help to differentiate  high grade MEC from  squamous  cell carcinoma. 
MEC that shows over expression of HER2/neu had lower survival rate106. 
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SALIVARY  DUCT CARCINOMA(SDC): 
High grade malignant tumor similar to duct breast carcinoma. Androgen 
receptors are frequently positive in this tumor. About 80% of this tumor shows 
diffuse/strong   membranous positivity for HER2/neu.19 
Ryuichi Murase et al107 stated [2011] that Androgen receptor[AR] expression 
in SDC patients are  sensitive to hormone therapy. 
A Etges  et al68 [2003] stated that HER2/neu  is associated with poor prognosis 
and  there was a  correlation  between  HER2/neu  oncoprotein expression and 
aggressive behavior in SDC.SDC are associated with high Ki-67 proliferative index. 
 
CARCINOMA EX PLEOMORPHIC ADENOMA65 
Immunohistochemically  Ca ex PA are strongly positive for AR,p53, HER2/neu 
and high Ki-67 labelling index.65 A recent study stated that S-100 protein play an 
important role in malignant transformation of ductal cells in pleomorphic 
adenoma.hence staining for S-100 would be a useful diagnostic marker in early phase 
of pleomorphic adenoma.129 PLAG1was specific for CA ex PA against other 
neoplasms65. 
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EVALUATION OF MALIGNANCY AND PROGNOSTIC FACTORS65: 
Ki -67 most frequently reported prognostic factor in MEC, SDC, CA ex PA. 
MEC and AdCC shows low recurrence when prognostic index is <5% and associated 
with poor prognosis when Ki-67>10%. 
p53 for AdCC and SDC and HER2/neu  are considered as prognostic factors. 
IHC: plays a limited, despite important role in diagnosis of salivary gland 
neoplasms. It is necessary to understand that IHC should be a method  to assist the 
final  diagnosis  but not change the  histopathological  based diagnosis.  . 
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OBSERVATION AND RESULTS 
 
               During the study period from September 2012 to August 2014, a total of 
13,916 specimens were received for  Histopathological examination, out of this 92 
specimens were of salivary gland lesions representing 0.6% as shown in the [table1,2], 
[chart-1,2]. 
Table 1 
Total number of specimens 13916 100 
Other lesions 13824 99.4 
Salivary gland specimens 92 0.66 
 
            Of the total 92 cases, 28 cases were diagnosed as non neoplastic , 64 cases as 
neoplastic lesions of which 41cases were benign and 23 cases were malignant. 
 Table  2: 
 INCIDENCE OF  SALIVARY GLAND LESIONS 
 
 
SEP-2011 
AUG-2012 
SEP-2012 
AUG-2013 
SEP-2013 
AUG-2014 TOTAL 
NO OF 
SPECIMENS 
 
5063 4505 4345 13,916 
SALIVARY 
GLAND 
LESIONS 
30 34 28 92 
PERCENTAGE 
 
0.59% 0.75% 0.64% 0.66% 
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Of the total 92 cases, 28 cases were diagnosed as non neoplastic and 64 cases 
as neoplastic lesions, of which 41cases were benign and 23cases were malignant as 
shown in table 2. Out of 41 benign  cases, 30 cases were Pleomorphic adenoma, 6 cases 
were Basal cell adenoma, 4 cases were Warthin’s tumor and one case of 
Myoepithelioma. The incidence of benign tumor was 64.06% which comprises of 
44.56%  of total salivary gland lesions. 
                     
Twenty three  cases were diagnosed as malignant, of which 12 were 
mucoepidermoid, 5 were Adenoid cystic carcinoma. Salivary duct carcinoma, 
carcinoma ex Pleomorphic Adenoma  constitutes about 2 cases each and basal cell 
adenocarcinoma and primary squamous cell carcinoma constitutes one case each.The 
incidence of malignant tumor was 35.94% which constitutes 35.94% of total salivary 
gland lesions. 
 
Table 3: 
 INCIDENCE OF NEOPLASTIC &NON NEOPLASTIC LESIONS 
   NON 
NEOPLASTIC 
NEOPLASTIC 
BENIGN 
NEOPLASTIC 
MALIGNANT TOTAL 
28 41 23 92 
30.44% 44.56% 25% 100% 
 
Incidence of benign tumor constitutes  44.5% and  malignant  tumors constitutes 
25% of total salivary gland lesions.  Incidence of non neoplastic lesions were  30.44% 
of total salivary  gland lesions[ table -3],[chart-3]. 
 
  
68 
 
Table 4:  
AGE DISTRIBUTION OF SALIVARY GLAND LESIONS 
 
       Among  the neoplastic lesions,  tumors  were    presented over a wide range of 20 
to 80 years of age. Of 64  neoplastic  lesions, the peak incidence for benign tumors  
were 30-50 years.  Malignant tumors shows  a wide range from 30-70 years  of  age. 
The mean age for non neoplastic lesions was  33.03 years, benign tumor was 43.39yrs, 
malignant tumor was 49.95 yrs. In  this study the youngest patient was 7 years and  the 
eldest  was 80 years of age as  in the table 4[chart-4]. 
 
 
 
 
 
AGE IN 
YEARS BENIGN 
MALIG
NANT 
NON 
NEOPLASTIC 
 
TOTAL PERCENTAGE 
1-10 1 1 2 4 4.35% 
11-20 1 - 7 8 8.69% 
21-30 6 1 7 14 15.22% 
31-40 10 5 3 18 19.56% 
41-50 12 5 5 22 23.92% 
51-60 4 5 1 10 10.86% 
61-70 6 4 3 13 14.14% 
71-80 1 2 - 3 3.26% 
Total 41 23 28 92  
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TABLE 5: 
SEX DISTRIBUTION OF SALIVARY GLAND LESIONS 
SEX BENIGN MALIGNANT NON NEOPLASTIC TOTAL 
PERCENTAGE 
OF TOTAL 
 
MALE 11 8 15 34 36.95% 
 
FEMALE 30 15 13 58 63.05% 
 
                   Among  the  92 cases of  total salivary gland lesions 58 cases were female  
which constitutes 63.05% and  34 cases were  male which accounts for 36.94% of 
salivary gland lesions. Female predominance was observed in all types of neoplastic 
lesions(58 in female and 34 in male). With male  to female ratio of 1 :1.7                              
[chart-5],[table-5]. 
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TABLE 6 
FREQUENCY OF SEX DISTRIBUTION OF SALIVARY GLAND TUMORS 
SEX BENIGN MALIGNANT TOTAL PERCENTAGE 
FEMALE 
 
30 15 45 70.32% 
MALE 11 8 19 
 
29.68% 
 
             Among the neoplastic lesions 45 cases  were female( 70.32%) and 19cases 
were male(  29.68% ) with male to female ratio of  1:2.36  The age  distribution of 
female was 7-80 years and in male it was 32-70 years of age as shown in table 6. 
 
TABLE 7: 
SITE DISTRIBUTION OF  SALIVARY GLAND LESIONS 
 SITE 
 
NONNEO 
PLASTIC BENIGN MALIGNANT TOTAL 
% OF 
TOTAL 
PAROTID 9 
 
37 12 58 63.04% 
SUBMANDIBULAR 5 
 
- 3 8 8.70% 
MINOR 
SALIVARYGLAND 15 6 5 26 28.26% 
 
                   Among 92 Cases of salivary gland lesions ,58 cases were seen  in parotid 
with the incidence of 63.04%,  26 cases were seen in  minor salivary gland with the 
incidence of 28.26% and 8 cases in submandibular gland with the incidence of 
8.70%[table-7],[chart-6]. 
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TABLE 8: 
SITE DISTRIBUTION OF SALIVARY GLAND TUMORS 
SITE BENIGN MALIGNANT TOTAL %OF TOTAL 
PAROTID 37 12 49 76.56% 
SUBMANDIBULAR 
GLAND - 3 3 4.68% 
MINOR SALIVARY 
GLAND 6 6 12 18.76% 
 
   Of  the 64 cases of neoplastic lesions 49 cases were seen  in parotid(76.56%), 
12 cases (18.76%) seen in minor salivary gland and 3cases (4.68%) were seen  in 
submandibular gland [table-8],[Chart-7]. 
               Of the 49 cases in the parotid  gland, Pleomorphic adenoma is the most 
common which constitutes  for 42.18%, followed by Mucoepidermoid carcinoma 
which constitutes 18.75%. In minor salivary gland  Adenoid cystic carcinoma was the 
most common accounting for 3.12% of all cases. 
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TABLE-9:                                           
SITE DISTRIBUTION OF BENIGN LESIONS 
BENIGN 
LESIONS 
 
PAROTID % 
SUB 
MANDIB
ULAR 
MINOR 
SALIVARY 
GLAND 
% 
PLEOMORPHI
C ADENOMA 27 42.18% - 3 4.68% 
BASAL CELL 
ADENOMA 4 6.25% - 2 3.12% 
WARTHIN’S 
TUMOR 4 6.25% - - - 
MYOEPI 
THELIOMA 1 1.56% - - 
- 
 
 
     Among  the benign lesions of parotid,  Pleomorphic adenoma is the most common 
accounting  for 42.18% followed by Basal cell adenoma and  Warthins  which accounts 
for (6.25%)[table-9],[chart-8]. 
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TABLE 10: 
 SEX DISTRIBUTION OF MALIGNANT LESIONS 
 
MALIGNANT TUMOR FEMALE MALE TOTAL %OF TOTAL 
MUCOEPIDERMOID 
CARCINOMA 9 3 12 52.17% 
ADENOID CYSTIC 
CARCINOMA 2 3 5 21.73% 
SALIVARY DUCT 
CARCINOMA 1 1 2 8.70% 
CARCINOMA EX PA - 2 2 8.70% 
BASAL CELL 
ADENOCARCINOMA 1 - 1 4.35% 
PRIMARY SQUAMOUS 
CELL CARCINOMA 1 - 1 4.35% 
 
                  Of   the 23 malignant lesions, Mucoepidermoid was the most common 
lesion  involving the  parotid(52.17%) followed by Adenoid cystic carcinoma (21.73%) 
as in table 10. The incidence of malignant tumor shows a female preponderance with 9 
cases (39.13%) of  mucoepidermoid [table-10],[chart-9]. 
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TABLE 11: 
SITE DISTRIBUTION OF MALIGNANT SALIVARY GLAND  TUMORS 
 
MALIGNANT 
TUMOR 
PAROTID % 
SUB 
MANDI 
BULAR 
% 
MINOR 
SAL 
GLAND 
% 
 
MUCO  
EPIDERMOID 
CA 
12 18.75% - - -  
ADENOID 
CYSTIC CA 
1 
 
1.56% 2 3.12% 2 3.12% 
CA EX 
PLEOMORPHIC 
ADENOMA 
1 1.56% - - 1 1.56% 
SALIVARY 
DUCT 
CARCINOMA 
-  1 1.56% 1 1.56% 
 
BASAL CELL 
ADENOCARCIN
OMA 
-  - - 1 1.56% 
 
PRIMARY 
SQUAMOUS 
CELL 
CARCINOMA. 
1 1.56% - - - - 
 
        Among the salivary gland tumors, malignant lesions  occur  most commonly in 
parotid  accounting  for 15 cases [23.43%]  followed by minor salivary gland 5cases 
[7.81%] and submandibular gland 3cases (4.68%) [table-11], [chart-10]. 
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TABLE 12: 
FREQUENCY OF NON NEOPLASTIC LESIONS 
NON NEOPLASTIC 
LESIONS MALE FEMALE TOTAL 
%OF 
TOTAL 
CHRONIC 
SIALADENITIS 5 3 8 28.57% 
MUCOUS RETENTION 
CYST 6 8 14 50% 
KIMURA’S DISEASE 1 - 1 3.57% 
KUTTNER TUMOR 1 - 1 3.57% 
BENIGN CYSTS 2 1 3 14.29% 
LYMPHOEPITHELIAL 
CYST - 1 1 3.57% 
 
              Non neoplastic lesions  are commonly seen in the age group of 20-40 years of 
age.Male preponderance  was seen   in  these  lesions with  15 cases of  male and 13 
cases of female. [table 12],[chart-11] 
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TABLE 13: 
SITE DISTRIBUTION OF NON NEOPLASTIC LESIONS 
  NON 
NEOPLASTIC 
 
PAROTID % 
SUB 
MANDI 
BULAR 
% MINOR SALIVARY % 
CHRONIC 
SIALADENITIS 
3 
 
10.72% 5 17.85% 0 0 
MUCOUS 
RETENTION 
CYST 
0 0 0 0 14 50% 
KIMURA’S 
DISEASE 
 
1 3.57% 0 0 0 0 
KUTTNER 
TUMOR 0 0 1 3.57% 0 0 
LYMPHOEPITH
ELIAL CYST 1 3.57% 0 0 0 0 
BENIGN 
PAROTID CYST 3 10.72% 0 
 
0 0 0 
 
              Among the non neoplastic lesions,  Mucous retention cyst  were the most 
common. It accounts  for 14 cases (50%)  in  minor salivary gland, followed  by 
chronic sialadenits  in submandibular   gland. One case  each of Kimura’s and  Kuttner 
tumor were reported in this study. [table-13],[chart-12] 
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TABLE 14: 
INCIDENCE OF ALL SALIVARY GLAND TUMORS 
LESIONS NUMBER PERCENTAGE 
PLEOMORPHIC ADENOMA 
 
30 46.87% 
BASAL CELL ADENOMA 6 9.37% 
WARTHIN’STUMOR 4 6.25% 
MYOEPITHELIOMA 1 1.56% 
MUCOEPIDERMOID CA 12 18.75% 
ADENOID CYSTIC CARCINOMA 5 7.81% 
SALIVARY DUCT CARCINOMA 2 3.13% 
CARCINOMA EX PLEOMORPHIC 
ADENOMA  2 3.13% 
BASAL CELL   ADENOCARCINOMA 1 1.56% 
PRIMARY SQUAMOUS  CELL 
CARCINOMA 1 1.56% 
 
The  benign tumor most common in this study was pleomorphic adenoma[ fig 
1,2] which accounts for 30cases. The  incidence  was  46.87% cases of total neoplasm 
and 73.17% of benign salivary gland tumors. Basal cell adenoma[ [figure11,12,13]  is 
the second most common benign tumor accounting for 9. 37% of all neoplastic  lesions 
and 14.63% of benign tumors. Warthin’s tumor[ figure14,15] accounts for 6 .25% cases 
of all neoplastic lesions and 9.76% of benign tumors. Myoepithelioma[figure 16] 
account for 1.56%  of neoplastic lesion  and 2.44% of benign lesions. 
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            Pleomorphic adenoma shows a peak incidence in 3rd- 5th decade of life with 
mean age of 43.97 yrs with female preponderance (58.54%).  Of  the  30 cases,  27 
arise from parotid and 3 cases from submandibular gland. Out of  6  cases of basal cell 
adenoma  4 cases arise in the Parotid and 2 cases from  minor salivary  glands. Out of 4 
cases of warthin’s  tumor,  all cases arise in parotid with a male preponderance. The 
mean age was 61 yrs. 
Among the malignant tumors, Mucoepidermoid [figure 17-23] was the 
commonest accounting for  18.75% of all neoplasms  and 52.17% of malignant tumors. 
The second most common tumor  was  Adenoid cystic  carcinoma  [ figure24,25] which 
constitutes about 7.81% of all neoplasms and 21.73% of malignant tumors. Salivary 
duct carcinoma[figure 27], carcinoma ex pleomorphic adenoma 2 case each accounting 
for 3.13% followed by  Basal cell adenocarcinoma[figure 26],primary squamous cell 
carcinoma[figure 28]  one case of  each  accounting  for 1.56% of all neoplasms [table-
14],[chart-13].   
Mucoepidermoid carcinoma shows a female preponderance[75%] with mean 
age   of  42.5yrs. Of the 12 cases  all arise from parotid  gland[18.75%].  The youngest 
patient reported was 7 years  old  female child.  
 Adenoid cystic carcinoma shows a male preponderance [60%]. Out of 5 cases  
one occur in parotid[1.56%],2 cases each in submandibular and minor salivary gland 
accounting for 3.12% of malignant tumors. 
 Of the 28 non neoplastic lesions, 14 were mucous retention cyst  [figure 29],8 
were chronic sialadenitis [figure30].  Non neoplastic lesions shows peak incidence in 
2nd to 3rd decade of life. Among 28 cases  8 cases occur in the parotid,7 cases occur  
submandibular gland. Remaining 14 cases occur in minor salivary gland.[chart-12] 
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FREQUENCY OF EXPRESSION OF p63 AND OTHER MARKERS IN 
SALIVARY GLAND TUMORS 
 
TABLE:15   p63  EXPRESSION  IN PLEOMORPHIC ADENOMA 
PLEOMORPHIC 
ADENOMA 
p63[ABLUMINAL 
CELLS] 
CK-7[LUMINAL 
CELLS] 
 CASES-1 POSITIVE POSITIVE 
CASE-2 POSITIVE POSITIVE 
CASE-3 POSITIVE POSITIVE 
CASE-4 POSITIVE POSITIVE 
  
In our study, p63 myoepithelial marker[figure35,36]  was studied in 4 cases of  
pleomorphic adenoma and all the abluminal cells [myoepithelial cells]were positive for 
p63. All luminal  cells were positive for CK-7[figure37]. Expression of myoepithelial 
cell marker p63 in Pleomorphic  adenoma  have confirmed  the role of myoepithelial 
cells in histiogenesis of this tumors.64  Immunohistochemical positivity of 
myoepithelial cell marker in Pleomorphic adenoma  indicates the origin of this tumor, 
is from intercalated duct  of salivary  gland. 
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TABLE 16: p63  EXPRESSION IN MUCOEPIDERMOID CARCINOMA  
MUCOEPIDERMOID 
CARCINOMA 
p63[INTERMEDIATE 
CELLS] 
CK-
7[MUCINOUS 
CELLS] 
Ki-67 
LOW GRADE POSITIVE POSITIVE <3% 
INTERMEDIATE 
GRADE POSITIVE POSITIVE <10% 
HIGH GRADE POSITIVE POSITIVE - 
                    
                    In  mucoepidermoid carcinoma , the  intermediate cells  shows positive  for 
CK-7, p63 [figure44] and mucocytes  shows  positive for CK-7[figure43]. Limited or 
lack of myoepithelial cells in mucoepidermoid carcinoma [figure44] indicate the 
minimal myoepithelial  differentiation  in   hisitogenesis of mucoepidermoid 
carcinoma. 
                 The absence of myoepithelial cells in excretory or striated ducts  of salivary 
gland and  negative staining  for myoepithelial markers in MEC suggest that it 
originates from excretory or striated duct component of salivary glands.  
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TABLE:17 
IHC MARKERS IN OTHER BENIGN TUMORS: 
TUMORS p63[ABLUMINAL CELLS] 
CK7[LUMINAL 
CELLS] Ki-67 INDEX 
BASAL CELL 
ADENOMA POSITIVE POSITIVE > 3% 
WARTHINS TUMOR POSITIVE[BASAL CELLS] POSITIVE 3% 
MYOEPITHELIOMA POSITIVE NEGATIVE - 
 
In basal cell adenoma the luminal cells are positive for CK-7 [figure39],the 
basaloid cells are positive for p63[figure-40]. While the luminal secretory material is 
positive for PAS by histochemistry [figure-12]. 
In myoepithelioma [figure48] the myoepithelial cells have taken the p63 ,while 
in Warthin’s tumor the luminal cells shows CK-7 positive[figure 41] and the basal cells 
shows p63 positive[figure 42]. 
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TABLE 18 :MARKERS IN OTHER MALIGNANT TUMORS 
ADENOID CYSTIC 
CARCINOMA 
CK-7 POSITIVE 
[LUMINAL CELLS] 
CD-117 POSITIVE 
[LUMINAL CELL] 
BASAL CELL 
ADENOCARCINOMA Ki-67 >50% POSITIVE 
SALIVARY DUCT 
CARCINOMA HER2/NEU 
MEMBRANE 
POSITIVE[2+] 
CK-7 
 
NEGATIVE 
PRIMARY SQUAMOUS 
CELL CARCINOMA 
 
CK-20 NEGATIVE 
 
In adenoid cystic  carcinoma the luminal cells are positive for CK-7[figure-
49]]and CD-117[figure-50].  The surrounding  myoepithelial cell/basal cells are 
positive for p63.  
As stated by Mino M et al ,59 CD-117 was previously reported as specific 
marker for Adenoid cystic carcinoma ,but recently it has been proved to be  non 
specific.65  However the intensity and extent of CD-117 staining is more in Adcc when 
compared to other tumors. 
 
BASAL CELL ADENOCARCINOMA: The inner luminal cells were positive for              
CK-7[figure 51] and Ki-67 index was > 50% in this tumor[figure-52]. 
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SALIVARY DUCT CARCINOMA 
Immunohistochemistry done with HER2/neu showed diffuse cytoplasmic 
positivity[figure53]. About 70-80% of salivary duct carcinoma showed  overexpression  
of HER2/neu and p53, with  more than half of the cases having   3+ HER -2 /neu 
positivity. 
 
PRIMARY SQUAMOUS CELL CARCINOMA : 
In our study IHC was done with CK-7 and CK-20, both were found to be 
negative [figure54,55]. This favors the diagnosis of primary squamous cell carcinoma 
over mucoepidermoid carcinoma which shows CK-7  positivity.10. 
      
 
  
     
 
 
 
 
 
 
 
 
 
 
Figure 3.Pleomorphic Adenoma showing squamous metaplasia.H&E(40x). 
Figure 2.Pleomorphic adenoma,-Ductal 
structures surrounded by myoepithelial cells 
H&E (10x) 
Figure 1 Pleomorphic adenoma with   
                 Solid glistening  grey white areas. 
                                                                                                                             
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.Pleomorphic adeoma with sebaceous differentiation.H&E(40x). 
 
Figure 4.Pleomorphic adenoma with 
cartilagenous areas. H&E (10x)   
Figure 5. Pleomorphic adenoma showing 
myxoid stroma with stellate cells.H&E(10x). 
. 
 
Figure 7.Pleomorphic adenoma with lipomatous areas.H&E(40x) 
 
 
    
 
Figure 8. Pleomorphic adenoma-Alcian 
blue:shows positive chondromyxoid areas. 
(10x) 
Figure 9.Pleomorphic adenoma- cartilagenous  
areas shows blue colour with Masson trichrome 
(40x). 
                      
 
 
 
 
 
 
 
 
 
 
 
Figure 10.Pleomorphic adenoma showing intraluminal PAS positive secrections(10x). 
 
    
 
 
Figure12.Basal cell adenoma shows PAS –
positive basement membrane (10x). 
Figure 11. Gross picture of basal cell adenoma  
shows a well circumscribed,solid light tan  
cut surface. 
                  
 
 
 
 
 
 
 
 
 
 
 
Figure 13.Basal cell adenoma trabecular type;shows cuboidal cell with bland 
nuclei.(10x). 
 
 
 
 
 
 
 
 
 
 
 
WARTHINS TUMOR:GROSS[patho no:830/14] 
Figure 14.Warthins tumor : shows grey white areas with cystic and 
papillary projections. 
        
Figure 15.Warthins tumor shows a papillary epithelial lining composed of two layers of 
epithelial cells with oncocytic features. H&E (10x). 
 
                            
 
 
 
 
 
 
 
 
 
 
Figure16: Myoepithelioma.showing fascicles of spindle cells with ductal 
structures.H&E(10x) 
          
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
  
Figure 19. Mucoepidermoid carcinoma low grade shows PAS positive in mucous 
cells.PAS stain (10x). 
 .        
Figure 17.Gross picture of  Mucoepidermoid 
Carcinoma -Low grade with cystic areas 
Figure 18.Gross picture of high grade 
Mucoepidermoid 
shows  predominantly solid areas. 
 Figure 20. Mucoepidermoid carcinoma low grade shows multiple cyst spaces lined by 
mucocytes admixed with intermediate cells.H&E (10x). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21.High power of mucocytes in low grade mucoepidermoid carcinoma. 
H&E (40x). 
        
 Figure 22.Mucoepidermoid carcinoma  intermediate grade.shows predominantly 
intermediate cells with few mucocytes. H&E (10x). 
 
 
Figure 23. Mucoepidermoid carcinoma high grade shows epidermoid cells with moderate 
nuclear pleomorphism.H&E (40x). 
 
 
GROSS PICTURE OF  ADENOID CYSTIC CARCINOMA 
 
Figure 24.Gross picture of Adenoid cystic carcinoma  firm ,tan with areas of 
haemorrhage. 
 
Figure 25:Microscopy of Adenoid cystic carcinoma  showing basaloid cells arranged in 
tubules and cribriform pattern.H&E(10x). 
  
 
 
. 
 
Figure 26.Basal cell adenocarcinoma.microscopy showing  basaloid cells with prominent 
nucleoli.H&E (10x). 
 
               
Figure 27.Microscopy of salivary duct carcinoma with central  
comedo like necrosis. H&E (10x). 
  
Figure 28.Microscopy of squamous cell carcinoma with 
prominent keratin pearl.H&E (10x). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NON NEOPLASTIC LESIONS. 
 
Figure 29.Mucus retention cyst shows cyst containing  mucin lined by columnar 
epithelium.H&E (10x). 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Chronic sialadenitis. Dilated ducts with lymphocytic infiltrate.H&E (10x). 
 
 
KIMURA’S DISEASE: 
 
 
 
Figure 33.Lymphoepithelial cyst shows undulating luminal surface lined by columnar 
epithelium with underlying dense lymphoid tissue.H&E(10x). 
 
  
                       
 
 
Figure 31 .Kimura disease- .Microscopy shows 
prominent lymphocytes,eosinophils and 
vascularization.H&E scanner  view . 
Figure 32. Kimura disease-H&E(40x). 
IMMUNOHISTOCHEMISTRY IN SALIVARY GLAND TUMORS. 
    
Figure 34a. P63 in  nuclei of both  myoepithelial  and basal cells  that surrounds the  
secretory ductal units. (10x). 
.  
Figure 34b .P 63 in normal intercalated duct- myoepithelial cells are positive ,(40x). 
 
 
 
  
 
 
 
 
 
   
 
 
             
 
 
 
 
 
 
 
 
Figure 35. P63 in Plemorphic adenoma 
myoepithelial cells are positive. (10x). 
    Figure36.P63 in  Pleomorphic adenomas-  the 
myoepithelial cells surrounding the luminal cells 
are positive for P63. (40x). 
 Figure 37.Pleomorphic Adenoma luminal cells are positive for cytokeratin-7 (10x). 
                    
 
 
 
 
 
 
 
 
 
     
 
 
 
 
          
Figure 38.Ki-67 in Pleomorphic adenoma-Ki-67 index < 1%.(40x). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39.Basal cell Adenoma luminal cells have taken cytokeratin-7 
(10x) 
Figure 40 .Basal cell Adenoma.- Myoepithelial cells surrounding the 
luminal cells have taken P63 10(x). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
Figure 41.Warthins tumor luminal 
epithelial cells are positive for 
cytokeratin-7 (10x). 
Figure 42.Warthins tumor basal 
cells are positive for P63(10x). 
  
            
 
 
 
 
 
 
 
 
Figure 43. Mucoepidermoid carcinoma. CK-7 has taken up  by the mucocytes  and 
intermediate cells(10x). 
 
 
 
               
 
 
 
 
 
       
 
Figure 44.  Mucoepidermoid carcinoma. P63 is expressed only in the intermediate  
epidermoid cells ,  shows absence of myoepithelial cells (10x). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.46 Ki-67 index<10% in Intermediate grade Mucoepidermoid carcinoma (10x). 
 
 
 
Figure 46. Ki-67 immunoprofile less 
than 10%  in intermediate grade 
Mucoepidemoid  carcinoma  (10x). 
Figure 45.CK-20 expression –negative in Mucoepidermoid 
carcinoma(10x). 
  
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
  
 
Figure 47.Her2/neu in Mucoepidermoid 
carcinoma shows diffuse positivity [2+].(40x). 
Figure 48. P 63 in Myoepithelioma-myoepithelial cells 
have taken p63 (10x). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50. CD-117  expression in Adenoid cystic carcinoma. Luminal cells are positive 
for CD-117(10x). 
 
    
Figure 49. Cytokeratin-7  expression  in Adenoid cystic 
carcinoma. Luminal cells are positive(10x). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
. 
Figure 51. Cytokeratin - 7 positive  in Basal cell 
adenocarcinoma.(10x). 
Figure 52. Ki -67 index in Basal cell adenocarcinoma 
>50% (10x). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53. Her2 /neu  expression in Salivary duct carcinoma 
shows 2+ positive.(10x) 
Figure 54.CK-7 expression negative  in Primary squamous 
cell carcinoma.(10x). 
 Figure 55. CK-20 expression  negative in  Squamous cell carcinoma.(10x). 
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DISCUSSION 
 
             The present study was conducted  in the Department of pathology, Thanjavur 
medical college for a period of three years. A total of 92 cases were studied with 
respect to incidence,age, sex,incidence, gross and microscopic features. 
 
I NCIDENCE PER YEAR OF SALIVARY GLAND TUMORS IN DIFFERENT 
SERIES 
  TABLE19: 
SERIES TOTAL NO OF TUMORS 
PERIOD OF 
STUDY 
NO OF CASES 
PER YEAR 
Vuhahula et 
al1082004 268 10 26.8 
Ito et al1092005 496 29 17 
ThomasKM 110et al 190 9 21 
Otoh et al 111 202 10 20.2 
Present study 64 3 21.33 
 
         In the present study  incidence of salivary  gland tumor  per year was 21.33%  
which correlates with  Thomas et al and  Otoh et al.  Vuhahula  et al108  has got a higher 
incidence than ours.Ito et al109 observed  a  very  low  incidence[chart-14]. 
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Table:20 
 FREQUENCY  OF BENIGN AND MALIGNANT  TUMORS 
SERIES TOTAL CASES BENIGN MALIGNANT 
Ito et al 109 335 67.5% 32.5% 
Vuhahula EA et 
al108  125 53.4% 46.4% 
Jones et al113 741 64.9% 35.1% 
Otoh et al 111 202 63.00% 37.00% 
Gupta et al114 113 69.90% 30.10% 
Our study 64 64.06% 35.94% 
 
   
             The frequency of occurrence of  benign tumors were more common when 
compared to malignant tumors  which was observed in present study as well as in the 
above series  in the present  study   the incidence of   benign tumor   was 64.06% and 
35.94% for malignant tumors [chart-15].  
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AGE DISTRIBUTION  OF TUMORS IN DIFFERENT SERIES 
TABLE 21: 
SERIES BENIGN MALIGNANT 
Thomas et al110 39 46 
Krishnaraj subha raj115 43 56 
Ahmed et al75 32.7 43.1 
Rewusuvan et al 117 72 49 
Satko et al118 47.41 52.59 
Felipe112 46.3 54 
Present study 43.39 49.95 
 
In most of the studies benign tumors occur at a younger age group than 
compared to malignant tumors. The results in the above series are correlated with other 
Indian studies . 
The mean age of  benign tumor was 43.39% and for malignant tumor was 
49.95% the present  study correlates with  krishnaraj subharaj,115Felipe PF,112 
Rewusuvan et al117 and  satko et al118[chart-16]                  
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TABLE 22: SEX  DISTRIBUTION OF TUMORS  IN DIFFERENT SERIES 
SERIES TOTAL BENIGN(M:F) MALIGNANT(M:F) 
Mohb Ayubet al119 1:1.4 1.9:1 1:3.3 
Budharaj et al120 1.1:2.0 1.0:1.0 1.0:2.0 
Gupta et al114 1.0:1.7 1.0:1.6 1.0:1.2 
Rewusuvan et al117 1.0:1.3 1:1.2 1:1.5 
Present study 1:2.56 1:3.1 1:1.8 
 
  In our study  there was  slight female preponderance in both benign and 
malignant tumors, similar to other studies.However Mohb  Ayub et al119 have observed 
a male preponderance.  
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TABLE 23: SITE DISTRIBUTION OF SALIVARY GLAND  TUMORS  IN 
VARIOUS STUDIES 
SERIES PAROTID SUBMANDIBULAR 
MINOR 
SALIVARY 
GLAND 
Arruda Morias et al122  72.6% 15.2% 12.2% 
Ahmed et al116  70% 18% 12% 
Davis et al123  75% 13.7% 11.3% 
Gupta et al114  67.80% 16.10% 16.15% 
Rewusuvan et al117 79% 18% 2% 
Chaterjee & Panda124  70% 18% 12% 
Felepi PF et al112 42.3% 6.8% 26.9% 
Our study 76.56% 4.68% 18.76% 
 
                 In the present study, parotid  was the commonest  site with the  incidence of 
76.56%, followed  by  minor salivary  gland with an incidence of  18.76%, 
submandibular gland with an incidence of 4.68%.  Similar results were observed by 
Rewusuvan et al117and Davis et al123 [chart17]. 
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TABLE 24:INCIDENCE OF PLEOMORPHIC ADENOMA IN VARIOUS 
STUDIES 
SERIES 
 
TOTAL NO 
OF 
TUMORS 
PLEOMORPHIC 
ADENOMA 
% OF 
TOTAL 
TUMORS 
% OF 
BENIGN  
TUMORS. 
Mohb Ayub et 
al119 204 127 62.25% 74.5% 
Rewusuvan et 
al117  198 84 64.12% 72.78% 
Vuhahula et 
al108 268 107 39.93% 73.8% 
Skolnik et 
al125 435 221 50.80% 73.20% 
Ito et al109 496 397 54.20% 80.30% 
Jones et al113 741 329 44.4% 68.4% 
FelipePF et 
al112 493 73 63.60% 85.0% 
Our study 64 30 46.87% 73.17% 
 
In the present study Pleomorphic adenoma was the most common tumor 
accounting for 73.17% of benign tumors  and 46.87% of all  tumors.This is similar to 
the results of other studies[chart-18]. 
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TABLE25 : SEX AND AGE DISTRIBUTION OF PLEOMORPHIC ADENOMA 
SERIES TOTAL NO OF TUMORS PA PEAK AGE M:F 
Mohb Ayub et 
al119  204 127 31-50 1:2.3 
Ahmed et al116 100 86 30-50 1.1:1.0 
Sharkey FE126. 338 203 20-40 1:1.8 
Rewusuvan et 
al117 198 84 14-79 1:2.1 
Thomas et al110  190 113 30-50 1:1.1 
Felipe PF et 
al112 493 493 31-50 1:1.55 
Our study 64 30 30-50 1:4 
 
The age incidence in present study correlates with  studies of Mohb Ayub et 
al119and  Ahmed et al.116 The peak  age  incidence was  4th decade in the present study. 
However  Rewusuvan et  al117observed a higher  age  incidence. Female  preponderance 
was  seen  in cases of Pleomorphic  adenoma in the present study similar to  other 
studies.          
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TABLE 26: LOCATION OF PLEOMORPHIC ADENOMA IN VARIOUS SITES 
SERIES PAROTID 
 
SUBMANDI 
BULAR 
MINOR 
SALIVARY 
GLAND 
Buddhraja et al120  82.80% 13.80% 3.40% 
Otoh et al111 80.00% 11.10% 18.00% 
Renehan et al127. 93.00% 3.4% 3.6% 
Rewsuvan   et al117 79.21% 28.5% 2.38% 
Our study 90% - 10% 
 
 
Parotid is the most common site for Pleomorphic adenoma followed by minor 
salivary glands. This was in accordance with other studies. No case was recorded in 
submandibular gland in the present study[chart-19]. 
 
 PATHOLOGY: 
GROSS: PA  ranges  in size from 1 to 6cms  with  solid, glistening, grey white areas 
[fig-1] and  with focal myxoid areas.[fig-5] which correlates  with other studies . 
 
MICROSCOPY:Shows features composed of myoepithelial, epithelial, myxoid and 
chondroid areas.[figure4,5]The epithelial components are composed tubules, ribbons,, 
small cysts and solid sheets. The cells were columnar to cuboidal. 
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The duct lumen contains  eosinophilic  material which  are  PAS positive 
[figure-10]. The myoepithelial cells were spindle, stellate, cuboidal and plasmacytoid  
arranged in sheets trabeculae. Stellate and spindle cells were suspended in  abundant 
myxoid stroma. 
Six of the cases showed chondroid differentiation[figure-4],two cases showed 
lipomatous areas [figure-7],three casess showed squamous metaplasia  [figure-3] and 
one case  showed sebaceous differentiation[fig-6]. 
Everson J W  noted  squamous  metaplasia   in pleomorphic  areas.   PAS    was 
positive in mucinous areas ,alcian  blue stain was positive for chondromyxoid  
areas[figure8]. 
 
TABLE 27:INCIDENCE OF BASAL CELL ADENOMA IN VARIOUS STUDIES  
 
SERIES 
TOTAL NO 
OF 
TUMORS 
BASAL CELL 
ADENOMA 
% OF 
BENIGN 
TUMORS 
% OF 
TOTAL 
TUMORS 
Krishnaraj 
subhashraj115 684 11 2.6% 1.6% 
Nagakar et al128 36 1 3.70% 2.77% 
Our study 92 6 14.36% 9.37% 
 
In this study, six cases of Basal cell adenoma was found which accounts for 
14.36% of benign tumors and 9.37% of of all salivary gland tumors. Basal cell 
adenoma is the second most common  benign tumor in our study. Incidence of Basal 
cell adenoma  in our study  was higher than  studies of Nagarkar et al.128  
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Our  study  shows  a  female  preponderance  with four  cases reported  in 
parotid and  two cases in minor salivary gland[chart-20]. 
 
PATHOLOGY : 
GROSS:  Excision  biopsy  shows  a well circumscribed  tumor with solid homogenous   
grey  white,firm nodule [figure-11]. 
 
MICROSCOPY: Tumors are  composed of  small ,round, uniform  basaloid  cells with 
large centrally placed nuclei, scant  basophilic  cytoplasm  arranged  in cords, 
trabeculae  and  sheets[figure-13]  separated by a fibrovascular stroma. Similar findings 
were recorded by Evans et al134. 
 
TABLE 28:INCIDENCE OF WARTHINS TUMOR IN VARIOUS STUDIES 
SERIES TOTAL NO OF TUMORS 
NO OF 
WARTHINS 
CASES 
% OF 
BENIGN 
TUMORS 
% OF ALL 
TUMORS 
Khazanchi et al129 88 06 10.70% 6.80% 
Nagarkar et al128  36 02 7.4% 5.55% 
FelipePF112 493 4 9.76% 7.3% 
Present study 64 4 9.76% 6.25% 
 
                  Warthin’s tumor was the third most common benign tumor in our study 
accounting for 6.25% of all salivary gland neoplasms and 9.76 % of benign tumors.  
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This correlates with the results of Felipe,112 khazanchi et al,129 while  Nagarkar 
et al128     noted a low incidence [chart-21]. 
 
 TABLE 29:AGE AND SEX DISTRIBUTION OF WARTHIN’S TUMOR 
 
SERIES 
TOTAL NO 
TUMORS 
WARTHIN’S 
TUMOR PEAK AGE M:F 
Sharkey126 et al 338 61 40-60 2.8:1 
Skolnik 125et al 435 46 60-70 4.7:1 
Rewuswan117 et 
al 198 38 40-60 2.1:1 
Felipe 112et al 
2012. 493 36 
40-70 
 
3:1 
Present study 64 4 40-60 
 
4:1 
 
              The peak age distribution of warthin’s tumor in present study was between             
40-60 years. Our study correlates with sharkey et al,126 rewuswan et al.117 Male 
predominance is  noted in our study  similar to Sharkey et al,126 Skolniket et al, 125 
Felipe 112[ 2012].  
GROSS:  Warthins tumor shows grey white  areas with slit like spaces with papillary 
projection[figure 14].     
Warthin,s  tumor is characterized  by double  layer  of cells, the outer layer of columnar 
cells  and inner layer of oncocytic  cuboidal cells arranged in papillary and glandular 
pattern. Stroma showed abundant lymphoid tissue with formation of lymphoid 
follicles[figure-15].  
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TABLE 30:LOCATION OF WARTHIN’S TUMOR 
SERIES 
NO OF 
WARTHINS 
TUMOR 
PAROTID SUBMANDI BULAR 
MINOR 
SAL 
Budhraja et 
al120  2 2 - - 
Skolnik et 
al125 46 46 - - 
Mohb Ayub 
et 9al11 12 12 - - 
Felipe112  30 29 1(3.34%) - 
Present study 04 04 - - 
 
        Our study showed four cases of warthin’s, all occurred  in parotid gland, this is 
similar to results from other studies done by  Budhraja et al,120 Skolnik et al125  and 
Felipe112 [2012][chart-22].              
 
MYOEPITHELIOMA: 
  One  case of myoepithelioma was seen in 31 year old female accounting  for 
1.5% of all salivary gland tumors and 2.44% of all benign tumors. This tumor was seen 
in minor  salivary gland. This  study correlates with Jones et al 113. 
 Microscopy: The tumor cells shows  spindle cells[figure 16] with central 
vesicular  nuclei and eosinophilic cytoplasm with occasional duct formation  similar to 
the observation of  Dardick I et al.130  
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TABLE 31: INCIDENCE OF MUCOEPIDERMOID CARCINOMA(MEC) IN 
VARIOUS STUDIES 
 
SERIES TOTAL NO TUMORS MEC 
% OF ALL 
TUMORS 
% OF 
MALIGNANT 
TUMORS 
Vahahula et al 
108
 
268 25 21.6% 46.6% 
Vargas et al131 124 13 10.48% 52.0% 
Panda et al124  315 26 8.26% 39% 
Felipe 112 493 39 7.9% 31.4% 
Our study 64 12 7.9% 52.17% 
  
            In our study 12 cases of mucoepidermoid carcinoma were seen comprising 
7.9% of all salivary gland tumors and 52.17%  of all malignant tumors. Vargas et al131  
in  their study of 124 tumors,  Mucoepidermoid  carcinoma constitutes 10.48% of all 
tumors. Panda et al,124   studied 315 cases of salivary gland of these,   Mucoepidermoid 
constitutes  8.26%.[chart-23]. 
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TABLE 32: AGE &SEX INCIDENCE OF MEC IN VARIOUS STUDIES  
SERIES TOTAL NO OF TUMORS 
TOTAL NO 
CASES PEAK AGE M:F 
Joneset al al113  741 85 51-60 1:1.6 
Vargas et al131  124 85 51-60 1:1.6 
Felipe112  493 39 31-70 1:1.33 
Present study 64 12 40-60 1:3 
 
 
                        Present study shows a slight  female predominance . Similar observation 
was made by Jones  et al,113 Felipe112[ 2012]. The peak age incidence of 
Mucoepidermoid carcinoma is seen in the age group of 40-60 years. The youngest age 
in our study is a 7 year old female child.  
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TABLE 33: LOCATION  OF MEC IN VARIOUS  STUDIES 
SERIES PAROTID SUBMANDI BULAR 
MINOR 
SALIVARY 
GLAND 
Nagarkar et al 128 80% - - 
Agarwal et al 132 78.6% 21.4% - 
Sharkey et al126 80.00% 4.00% 16% 
Ochicha et al133 49% 26% 24% 
Present study 100% - - 
 
Parotid gland is the most common site for Mucoepidermoid carcinoma in our study. 
Observations are similar to Nagarkar et al.128  In our study all the cases  were  seen in 
parotid and none from minor salivary gland  similar to Nagarkar et al,128Agarwal et 
al.132 
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 TABLE 34:HISTOLOGICAL GRADING  OF MEC  
 
SERIES NO OF MEC LOW INTERMEDIATE HIGH 
Renehan et 
al127  38 87.4% - 2.6% 
Goode et al134 234 76.06% 7.69% 13.24% 
Present study 12 
 
83.34% 8.33% 8.33% 
 
 
The present study showed a preponderance of low grade mucoepidermoid 
carcinoma[83.34%], similar to results of renehan et al,127Goode et al134[chart-24]. 
GROSS: Grey white to pink areas with,cystic spaces in low grade  cases [fig-17]  and 
predominantly solid areas  in high grade cases[fig-18]. 
MICROSCOPY: In our study, tumors showed three types of cells  such as mucous 
cells, epidermoid cells and intermediate cells[figure20-23].  Mucous cells are PAS 
positive[ fig-19]. Lymph node metastasis was seen in a case of high grade 
Mucoepidermoid  carcinoma. 
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TABLE35:INCIDENCE OF ADENOID CYSTIC CARCINOMA  IN VARIOUS 
STUDIES 
SERIES TOTAL NO OF TUMORS 
ADENOID 
CYSTIC 
CARCINOMA 
% OF 
TOTAL 
TUMORS 
% OF 
MALIGNANT 
TUMORS 
 
Rewusuwan 
 et al 117 
198 18 10 24.74% 
Nagarkaret al128  36 2 5.5% 25% 
Vargas131 et al 124 5 4.03% 20.0% 
Felipe112 [2012] 493 12 7.4% 16.4% 
Present study 64 5 7.81% 21.73% 
 
In the present study Adenoid cystic carcinoma constituted 7.81% of all tumors 
of salivary gland  tumors and 21.73% of malignant salivary gland tumors. Similar   
results were obtained in studies of Felipe112[2012] . 
However  Rewusuvan et al 117  observed  18 cases  out of 198  salivary gland 
tumors   which   showed  slight  higher  incidence  than other studies. 
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TABLE 36: AGE AND SEX INCIDENCE OF ADENOID CYSTIC 
CARCINOMA 
SERIES TOTAL NO OF CASES 
ADENOID 
CYSTIC 
CARCINOMA 
PEAK AGE M:F RATIO 
Rewusuvanet 
al 117 198 18 40-50 1:1.5 
Agarwal 
 et al132 147 11 35-64 1.2:1.0 
Sharkey FE126 338 07 41-60 1.0:1.3 
Filipe112 493 12 31-70 3:2 
Present study 64 5 41-60 1:0.66 
 
           Present study showed age range from 41-60 years  with  mean age of 40.87 years  
which corresponds to Sharkey FE et al126 and  Rewusuvan  et al117 with a mean age of 
46.38 years .  Our study showed a slight  male preponderance  compared to  other 
studies. 
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TABLE 37: SITE DISTRIBUTION OF ADENOID CYSTIC CARCINOMA 
SERIES PAROTID SUBMANDIBULAR 
MINOR 
SALIVARY 
GLANDS 
Vihuhala et al108 16.3% 37.0% 38.3% 
Pour et al135 46.70% 0.67% 46.60% 
Present study 1.56% 3.125% 3.125% 
 
 
In the present study only one case occurred  in parotid which accounts for 1.56% 
and two cases each occurring in  submandibular and  minor salivary gland accounting 
for 3.125% each.  Other   studies  showed a  preponderance of minor  salivary gland  
for Adenoid cystic carcinoma. 
Microscopy: Showed predominantly  cribriform  and tubular  pattern  with 
basaloid cells   with   angulated  hyperchromatic  nuclei with scant cytoplasm separated  
by a hyaline stroma [figure 25].Similar findings were obtained by Auclair Ellis and 
Gnepp. A variable combination of  all three  patterns can occur in same tumor. One 
case shows extensive hyalinization. 
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SALIVARY DUCT CARCINOMA: 
In our study two cases of salivary duct carcinoma was reported one in submandibular 
gland, other in minor salivary gland in the age group of 50-70 years. The incidence was 
8.70% of malignant tumors and 3.13% of all salivary gland tumors. 
MICROSCOPY: Showed intraductal component  with  cribriform, solid, papillary 
pattern with central comedonecrosis as stated by  Nagao et al. 82   Our case showed  
ductal components  with  central  comedo necrosis.[fig- 27] 
Meyers and Ferris et al [2007] reported a incidence of 9% in his studies.  
 
CARCINOMA EX PLEOMORPHIC ADENOMA: 
         Felipe112 [2012 ] in their series of 493 cases observed an incidence  of 
1.6%[malignant tumors] of ca ex pleomorphic adenoma.  
         In another study by Mag135 et al [2010 ] an incidence of 28.57% was reported . 
In our study 2 cases of Carcinoma  ex  pleomorphic  adenoma were  reported with an 
incidence of 8.70% of malignant tumors and 3.13% of all salivary gland tumours. 
Microscopy: Showed  an  infiltrative growth composed of pleomorphic cells 
with  hyperchromatic  nuclei and moderate  amount of cytoplasm  arranged singly and 
in groups amidst myxoid stroma. 
 
BASAL CELL ADENOCARCINOMA 
In our study one case of basal cell adenocarcinoma of  70 years of age  was 
reported which accounts for 4.34% of malignant tumors and 1.56% of all salivary gland 
tumors.  
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 Histopathological examination  reveals basaloid cells[fig-26]  arranged in  solid 
and  tubular arrangements with infiltrating pattern as stated by barnes et al.136   This 
tumor arise primarly from parotid[80%]of older individual, most cases arise de 
novo[77%]  but some cases  arise from pre existing   basal cell adenoma[23%]. 
 
 PRIMARY  SQUAMOUS CELL CARCINOMA : 
Primary squamous cell carcinoma can occur in salivary gland. It accounts for 
1.6%  of  primary epithelial salivary gland tumors with a mean  age of 60.5 years.41 
   In the present study  a single case  was reported with an incidence of 4.34% of 
malignant tumor and 1.56% of all salivary gland tumor.  This case occur in 
submandibular region [figure-28]. 
 Rasp G et al 141reported a primary squamous cell carcinoma  in  a child .In the   
present study we reported a case of 70 years female. 
 
NON NEOPLASTIC LESIONS 
MUCOUS RETENTION CYST: 
 In  our study we reported 14 cases of mucous retention cyst  which accounts 
for 50% of all non neoplastic lesions. All the  cases occur in minor salivary gland with 
a slight female predominance. 
MICROSCOPY: Showed cyst lined by cuboidal to columnar epithelium with lumen 
filled with eosinophilic material[fig-29], inflammatory material composed of 
neutrophils, lymphocytes  and histiocytes   similar to the findings of sajeevan TP et al2 . 
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CHRONIC SIALADENITIS: 
Among 28  non neoplastic lesions, chronic  sialadenitis[fig-30]  accounts for 8 
cases which accounts for 28.57% of all non neoplastic  lesions. Of the 8 cases five 
cases occur in submandibular gland (17.85%) and 3 cases occur in parotid(10.72%) 
with a male predominance . 
Seifert et al142 stated the etiological classification of sialadenits 
 
CHRONIC SCLEROSING SIALADENITIS:[KUTTNER TUMOR] 
 In our study we reported a single case  in submandibular region  which 
constitutes 3.57% of non neoplastic  cases. 
 Kuttner tumor occurs exclusively in the submandibular  region  as stated by 
Sadayuki. K B et al138 
Wah cheuk and chan 139 stated that kuttner tumor is characterized  histologically 
by preservation of lobular architecture, lymphoid follicle formation, thickening of inter 
lobar septa by sclerosed tissue,variable loss of acini and preservation of acini with 
periductal fibrosis. 
 
IMMUNOHISTOCHEMISTRY IN SALIVARY GLAND TUMORS: 
p63 IN PLEOMORPHIC ADENOMA AND MUCOEPIDERMOID 
CARCINOMA: 
In present study, four cases of pleomorphic adenoma  were selected for  
myoepithelial  marker p63 [figure-35,36].  All the cases the abluminal cells  have taken 
p63, which  implies  the origin of pleomorphic adenoma from intercalated duct 
component. 
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In mucoepidermoid  carcinoma IHC was done with p63.  All the  cases, 
intermediate epidermoid cells have  taken  p63, [fig 44] but  not the myoepithelial  
cells. This confirms the origin of MEC  from excretory or striated duct component of 
salivary gland  
Similar results were observed by Batsakis et al143 ,Loyala and souse et 
al144[1998]   Marucci and Foschini145 [2002] et al.145and Nago et al 65. 
 
 MARKERS IN BENIGN TUMORS 
CK-7 was taken by the luminal cells[fig-37] of Pleomorphic adenoma as 
reported by Naga et al65. 
Ki-67 index in PA was 1% in present study[fig-38] which correlates with studies 
done by Anna kananceva et al140 
  In Basal cell adenoma the luminal cells are positive for CK-7 [figure-39] and 
surrounding myoeppithelial cells are positive for P63[fig-40] which correlates with the 
studies of  Edwards PC et al.146  Ki-67 labelling index was <3%  which correlates with 
Everson and Nago et al10. 
Warthin’s tumor  luminal cells  are positive for CK-7[fig-41] and basaloid cells 
are positive for p63[fig-42] as stated by Peigu et al  studies.19 
 In present  study a single case of myoepithelioma was stained with P63[fig-48],which 
has taken the nuclear staining as stated by Dardick et al147 [1989]. 
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 MARKERS IN MALIGNANT SALIVARY GLAND  TUMORS 
 In  Mucoepidermoid carcinoma  CK-7 has taken up by the mucocytes and 
intermediate cells [fig- 43] as stated by Maruya  et al.70  In  present  study,  MEC  was 
positive for CK-7 [fig-43] and negative for  CK-20[fig 45]   stated by  NikitakisN G et 
al137. 
Ki 67 labelling index in low grade MEC was found to be negative, whereas  in  
intermediate  MEC Ki-67 labelling index was found to be 10%.[fig-46] 
In MEC when the Ki-67 Index is < 5% there was no recurrence, when Ki-67 
index >10% associated   with  poor  out come65. 
In present  study HER2/neu expression was  done in  one case of MEC- 
intermediate grade and it was found to diffuse and cytoplasmic  membrane  positivity 
with grade 2 positive[fig -47]. 
Press  MF148 et al stated  that  40% cases of MEC are positive for HER2/neu and 
these cases are associated with poor prognosis. 
In  Adenoid  cystic carcinoma , the  luminal cells was found to be positive for 
CK-7[fig -49] and the  basal cells were positive for p63 as stated by Chen JC et 
al49[1988] . 
  Luminal  cells of Adenoid cystic carcinoma  are intensively positive for  CD-
117[fig-50] as stated by Holst VA150 et al. 
 Amoueian 151et al  stated that Ki-67 expression in Adenoid cystic carcinoma  
was found to be in the range of 0-85%. 
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In present study one case of basal cell adenocarcinoma was found to be CK-7 
positive [fig-51] and Ki-67 index  of  >50%[  figure-52]as stated  by Nago et al152. 
In present study 2 cases of salivary duct carcinoma shows diffuse and strong 
membraneous staining for HER2/neu[fig-53]  as stated by Jaehne 153   et al.  Similar    
results were  observed by Etges1 et al154 [2003]. 
 In  present study a single  case of primary squamous cell carcinoma  shows 
CK-7 and CK-20 negative[fig-54,55] as stated by Nikitakis NG et al137 2004 . 
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CONCLUSION 
Out of 13,916 general biopsies received in Thanjavur medical college during 
September 2012- August 2014 , 92 cases were salivary gland  lesions  accounting   for 
an  incidence of 0.6%. 
1.  Peak incidence of benign salivary gland lesion was in the age group of  30-50 
years  and  in  malignant lesions  it was  in the age group of 30-70 years. 
2. The mean age for benign tumors  was 43.39 years and in malignancy  it  was 
49.95 years. 
3. Salivary gland lesions shows  a female preponderance  with  male to female 
ratio of 1 : 1.7. 
4. Among the 64 cases of salivary gland tumors majority were found  in the 
parotid accounting for 76.56% followed by minor salivary gland 18.76% and 
submadibular  gland 4.86%. 
5. Inflammatory lesions were more common in minor salivary gland followed by 
submandibular gland. Benign tumors were more common  in parotid whereas in 
minor salivary  glands,  malignant tumors  were more common. 
6. Most common benign salivary gland tumor  in  present study is  Pleomorphic 
adenoma with an  incidence of 73.17%   followed  by  Basal cell adenoma 
which accounts for 14.63% . 
7. Most common malignant salivary gland tumor was Mucoepidermoid  carcinoma 
accounting for 52.17% of malignant  tumors  followed by Adenoid cystic 
carcinoma. 
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8. Expression of p63 in Pleomorphic adenoma had confirmed the role of                             
myoepithelial cells in the histiogenesis of this tumor and lack or minimal 
expression of p63 in Mucoepidermoid  indicates minimal  myoepithelial  cell 
differentiation . 
9. Cytokeratin -7 is expressed in the luminal cells of Pleomorphic  adenoma, Basal 
cell adenoma, Warthin’s tumor, Adenoid cystic carcinoma and Basal cell 
adenocarcinoma. 
10. Ki-67 is  the most frequently used prognostic markers in malignant  salivary 
gland  tumors. HER2/neu is also used as a prognostic marker in Salivary duct 
carcinoma. 
11. Histopathology  is the gold standard  for  the diagnosis of salivary   gland 
tumors. Immunohistochemistry plays  a limited, even though important role in 
the diagnosis of salivary gland tumors when the diagnosis is uncertain. 
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                                       LIST OF ABBEREVATIONS USED 
AdCC-Adenoid cystic carcinoma 
AR- Androgen receptor 
BCA-Basal cell adenoma 
Ca- carcinoma 
CEA- carcinoembryonic antigen. 
CK-cytokeratin 
C ex PA-carcinoma ex Pleomorphic Adenoma 
E-Eosin 
ER-Estrogen receptor 
EMA-Epithelial membrane antigen 
FNAC-Fine needle aspiration cytology 
GFAP-Glial fibrillary acid protein 
 H-  Hematoxylin 
IHC-Immunohistochemistry 
LESA;-Lymphoepithelial sialadenitis 
MEC-Mucoepidermoid carcinoma 
MUC-Mucin 
PA-Pleomorphic adenoma 
PAS-Periodic acid Schiff 
PLGA-Polymorphous low grade adenocarcinoma. 
PR-  Progesterone receptor. 
SCC- Squamous cell carcinoma. 
SDC- Salivary duct carcinoma 
SMA-Smooth muscle Actin 
WHO-World health organization 
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ANNEXURE – II 
PROFORMA FOR SALIVARY GLAND TUMORS 
Name :                         Age :           Sex :              IP No : 
WD  No : 
Residence :                                                                    Occupation : 
Unit :  
Marital status :                                                               D.O.A : 
No. of children :                                                             D.O.S : 
Socioeconomic status :                                                   D.O.D :  
Education :  
HISTORY OF PRESENTING ILLNESS :  
1. Swelling  
A.   Site 
B. Side  Right / Left 
C. Unilateral / Bilateral 
     2. Duration 
     3. Onset -  Acute / chronic 
     4. Progression – Gradual / Rapid 
     5. Local changes 
 A. Pain  
 B. Edema 
 C. Cellulitis 
 D. Discharging sinus  
     7. Associated symptoms 
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A. Facial nerve involvement 
 Drooling of saliva 
 Exposure keratitis 
 Deviation of angle of mouth 
B.  Inflammatory symptoms 
 Fever 
 Malaise 
 Pain 
 Anorexia 
PAST HISTORY  
   History of similar illness before 
FAMILY HISTORY 
   Similar complaints of 1st degree relatives 
PERSONAL HISTORY 
   Smoking / Alcoholism 
LOCAL EXAMINATION 
   Swelling  
   Skin over the swelling  
   Salivary duct 
   Movements of jaw 
   Examination of facial nerve 
 
REGIONAL LYMPH NODE STATUS  
   Site 
   Size 
   Number 
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   Consistency 
   Mobile / fixed 
   Ipsilateral / Contralateral / Bilateral 
SYSTEMIC EXAMINATION 
   CVS: 
   RS: 
   Abdomen: 
   CNS; 
INVESTIGATIONS : 
   Urine examination 
   Routine haemogram 
  X – Ray 
   USG 
   CT/MRI 
   FNAC DIAGNOSIS 
   HPE DIAGNOSIS 
 
 
 
 
 
PLAN OF TREATMENT  
   Simple excision 
   Superficial parotidectomy 
   Radical excision 
   RT/CT 
                                                             Signature of the Medical Officer  
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ANNEXURE – III 
WHO HISTOLOGICAL CLASSIFICATION OF TUMORS OF THE 
                                 SALIVARY GLANDS[WHO-2005] 
MALIGNANT EPITHELIAL TUMORS 
Acinic cell carcinoma 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
Polymorphous low grade carcinoma 
Epithelial – myoepithelial carcinoma 
Clear cell carcinoma – not otherwise specified 
Basal cell adenocarcinoma 
Sebaceous carcinoma 
Sebaceous lymphadenocarcinoma 
Cystadenocarcinoma 
Low grade cribriform cystadenocarcinoma 
Mucinous adenocarcinoma 
Oncocytic carcinoma 
Salivary duct carcinoma 
Adenocarcinoma – not otherwise specified 
Myoepithelial carcinoma 
Carcinoma ex pleomorphic adenoma 
Carcinosarcoma 
Metastasizing pleomorphic adenoma 
Squamous cell carcinoma 
Small cell carcinoma 
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Large cell carcinoma 
Lymphoepithelial carcinoma 
Sialoblastoma 
BENIGN EPITHELIAL TUMORS  
Pleomorphic adenoma 
Myoepithelioma 
Basal cell adenoma 
Warthin’s tumor 
Oncocytoma 
Canalicular adenoma 
Sebaceous adenoma 
Lymphadenoma 
 Sebaceous  
 Non-sebaceous 
Ductal papillomas 
 Inverted ductal papilloma 
 Intraductal papilloma 
 Sialadenoma papilliferum 
Cystadenoma 
SOFT TISSUE TUMORS 
Hemangioma 
HEMATOLYMPHOID TUMORS 
Hodgking’s lymphoma 
Diffuse large B cell lymphoma 
Extranodal marginal zone B cell lymphoma 
SECONDARY TUMORS 
 
  
123 
 
ANNEXURE – IV 
STAINING TECHNIQUES. 
HEMATOXYLIN AND EOSIN STAIN 
Preparation of the solution : 
Distilled water – 1000ml. 
Ammonium alum – 100gm. 
Haematoxylin  – 5gm. 
Absolute ethyl  alcohol – 50ml. 
Mercuric   Oxide – 2.5gm. 
 100gm of ammonium alum dissolved in 1000ml of distilled water by heating 
and shaking at 60oC. Add solution of 5gm haematoxylin in 50ml of absolute ethyl 
alcohol and bring rapidly to boil. When it begins to boil, remove from flame and add 
2.5gm of mercuric oxide. Mix by swirling gently. 
EOSIN STAIN 
Eosin Y  – 1gm. 
Distilled water  – 20ml. 
95% ethanol  – 80ml. 
Glacial acetic acid  – 0.2ml. 
Dissolve 1gm eosin Y in 20ml of distilled water and add 80ml of 95% ethanol and 
0.2ml of glacial acetic acid. 
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          PROCEDURE 
 Bring sections to water. 
 Harris’s hematoxylin for 15 minutes. 
 Rinse in tap water. 
 Differentiate in 1% acid alcohol – 3 to 4 quick dips. 
 Rinse in tap water. 
 Blue by placing in scott’s tap water until the section appear blue. 
 Wash in running tap water for 10 -20 minutes. 
 Stain with eosin for 15 seconds to 2 minutes depending on the age of the 
 eosin. 
 Rinse in tap water. 
 Dehydrate in 95% alcohol. 
 Absolute alcohol – at least 2 changes. 
 Xylene – 2 changes. 
 Mount in DPX mountant. 
RESULTS : 
 Nuclei – Blue. 
 Cytoplasm, RBC, Keratin – Pink. 
 Eosinophilic granules – Orange Red.  
 
 
 
 
  
125 
MASSON’S TRICHROME STAIN (MTS) 
TECHNIQUE 
1. Section to water. 
2. Stain in celesatine blue  for 5 minutes. 
3. Rinse in water. 
4. Stain in meyer’s haemalum for 5-10 minutes. 
5. Wash in running tap water for 10 minutes. 
6. Rinse in distilled water. 
7. Stain in acid fuchsin solution for 5 minutes. 
8. Rinse in distilled water. 
9. Differentiate and  mordant in a koplin jar containing 1% phosphormolybdic 
acid. 
10. Without rinsing place slide on a cold staining rack and add just enough aniline 
blue solution to cover section for 5 minutes. 
11. Rinse in distilled water. 
12. Differentiate in aqueous 1 percent acetic acid to remove excess aniline blue. 
13. Treat section in alcohol 1 percent acetic acid for 30 seconds. 
14. Dehydrate in absolute alcohl. 
15. Clear and mount. 
RESULT: 
Nuclei-blue to black. 
Cytoplasm-red. 
Collagen fibres-blue(or green0 
Mucin-blue(or green). 
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PERIODIC ACID SCHIFF TECHNIQUE 
SOLUTION REQUIRED: 
A) 0.5% PERIODIC ACID 
 periodic acid -0.5gm 
distilled water-100ml. 
B) SCHIFF’S REAGENT 
Basic fuschin-1gm 
Sodium metabisulphite ,anhydrous 1gm 
Distilled water-200ml 
N/1 hydrochloric acid 20ml 
Boil the distilled water; Add basic fuchsin and stir, cool to 50ºC.then filter and 
add hydrochloric acid, cool to25ºC and add Sodium  metabisulphite. This solution is  
ready for use when it become nearly colour less,which may take two days in the 
dark.(Alternately activated charcoal may be added to the solution,shaken and 
filtered.).If the solution become recoloured it should be discarded.  
TECHNIQUE: 
1.Section to water. 
2.Periodic acid 0.5% for 5 minutes. 
3.Rinse in distilled water. 
4.Schiff’s reagent for 15 minutes. 
5.Rinse in the three fresh changes of sulphuric acid for 2 minutes. 
6.Wash in running tap water for 5 minutes. 
7.Counter stain in mayer’s haemalum for 30 seconds. 
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8.Wash in running tapwater for 5 minutes. 
9.Dehydrate,clear and mount. 
 
RESULTS: 
Positive material; Magenta colour. 
Nuclei: Faint grey. 
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ANNEXURE-V 
IMMUNOHISTOCHEMISTRY 
 
PREPARATION OF SOLUTIONS:  
Citrate buffer solution- antigen retrieval solution 
Trisodium citrate: 2.94 gm  
1 N Hydrochloric acid: 5ml  
Distilled water: 1000 ml  
Required pH is 6.0, which are obtained by titration with 1N HCl.  
Tris Buffer Saline (TBS) - wash buffer  
Sodium chloride: 8gms  
Tris (hydroxymethylamine): 0.605gms  
1 N Hydrochloric acid: 4 ml  
Distilled water: 1 litre  
Required pH is 7.6, which are obtained by titration with 1N HCl.  
Preparation of chrom alum coated slides:  
Potassium dichromate: 50 mgs  
Gelatin: 300 mgs  
Distilled water: 100 ml 
Potassium dichromate is added to distilled water and then boiled to 60◦C. Gelatin is 
then added slowly to it. Glass slides are then dipped in this solution and dried 
overnight.  
After taking the required sections onto the coated slides, it is baked overnight at 45°C 
in the autoclave. The next day, the slides are taken for the procedure.  
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ANTIGEN RETRIEVAL:  
The slides are arranged in a metal racket and placed in citrate buffer inside the pressure 
cooker, and allowed to boil up to three whistles. 
 
Procedure: 
1. Dewax the section in xylene(15 minutes each, 2 changes) and then in decreasing 
grades of alcohol then finally bring the sections to running tap water followed by 
distilled water. 
2.  Antigen retrieval using TBS by pressure cooker method  
3. Cool to room temperature in running tap water for 20 minutes.  
4. Wash in TBS -2 changes for 5 minutes each.  
5.  Drain and cover the sections with peroxidise block (endogenous peroxidise blocking 
agent) for 15 minutes.  
6. Wash in TBS -2 changes for 5 minutes each.  
7. Drain and cover the tissue sections with power block for 15 minutes  
8. Drain and blot the excess power block.  
9. Cover the sections with the respective primary antibody for 90 minutes.  
10. Wash in TBS -2 changes for 5 minutes each.  
11. Drain and cover the sections with super enhancer for 30 minutes.  
12. Wash in TBS -2 changes for 5 minutes each.  
13. Drain and cover the tissue sections with secondary antibody (HRP-horse raddish 
peroxidise) for 30 minutes.  
14. Wash in TBS -2 changes for 5 minutes each.  
15. Drain and cover the tissue sections with DAB (DiaminoBenzidine) substrate buffer 
for 5-10 minutes (depending on the time suggested in the supplied kit)  
16. Wash in distilled water, counter stained with haematoxylin, clear in xylene and 
mount with DPX.  
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